



human.
technology.
styria.



Medical University of Graz

Innovative Science for Successful Business

4th Partnering Day
for Biomedical Research

October 18, 2007

Abstractbook



Development and strengthening of cooperation between innovative companies and university scientists in the field of life sciences will be the focus of the 4th international Partnering Day. This event is jointly organized by the Medical University of Graz, the Cluster Human.technology Styria and the Innovation Relay Centre Austria

The Partnering Day will offer the possibility, to present your technological know-how to regional and international enterprises in the sectors of biotechnology, pharmaceutical industry, medical and biomedical technology, medical and molecular diagnostics, medical informatics as well as implantation und transplantation technologies.

Scientists and companies will have the opportunity to establish contacts, to present scientific issues with industrial relevance and to identify new ways for cooperation.



Companies profit...

... from the technological know-how of the Medical University of Graz and of the life sciences department of other universities. You are welcome to establish contacts to scientists from all fields of medical research, in order to efficiently promote your development. Illustrate your expertise and communicate your requirements concerning research and technology. Present your possibilities to enter into research cooperation either during a short talk, on a poster or during a bilateral dialogue.

Broad technology platform

Researchers of the Medical University of Graz and of other life sciences universities as well as extramural research organisations are invited. This platform facilitates the discussion of a broad spectrum of biomedical topics. Furthermore the Partnering Day offers the possibility of networking between the attending enterprises.

Researchers profit...

... from the possibility to contact regional and international companies. Enterprises from all fields of biomedicine are invited. Your conceptions concerning research and development are sought-for. Benefit from the possibility to present your strengths to companies. Illustrate your requests to strong partners from industry. During individual discussions you will get into face-to-face contact with representatives from industry.

PROGRAM

9.00 - 9.05	Mag. ^a Kristina Edlinger-Ploder	Styrian minister of science, research, transport and technology	Welcome and Introduction
9.05 - 9.10	Univ.-Prof. Dr. Hellmut Samonigg	Vice-Rector for Strategy and Innovation	Welcome and Introduction
9.10 - 9.15	Univ.-Prof. Dr. Andreas Tiran	Head of the Center for Medical Research	Welcome and Introduction

Key Note Lecture

9.15 - 9.45	L01	Priv.-Doz. Dr. Martin Stetter	Siemens Corporate Technology	IT Solutions and Databases - Learning Systems
-------------	-----	-------------------------------	------------------------------	---

Short Talks

9.45 - 9.52	L02	Dr. Karine Sargsyan	Medical University of Graz - Res. Infrastr. & Res. Man. - Biobank	NUBI - Nutrition and Bioefficacy
9.52 - 9.59	L03	Dr. Frank Sinner	BioNanoNet Forschungsgesellschaft mbH	Development and coordination of (applied) research projects
9.59 - 10.06	L04	Dr. Günter Schreier	Austrian Research Centers GmbH - ARC, Biomedical Engineering / eHealth	Web-based IT platform for Biomedical/Translational research
10.06 - 10.13	L05	Dipl. Ing. Donat Elsener	REMP AG	Establishing Biobanking facilities and SOPs
10.13 - 10.20	L06	Yurii Babich	Centre of diomedical electroengineering	Electrodynamic Introscopy (EI)
10.20 - 10.27	L07	Dr. Wolfgang Waldhauser	JOANNEUM RESEARCH Forschungsgesellschaft mbH, Laser Center Leoben	We are developing functional thin coatings for biomedical applications (e.g. implants and prostheses, biosensors, biochips).
10.27 - 10.34	L08	Dr. Claudia Preininger	Austrian Research Centers GmbH - ARC / Department of Bioresources	protein chips: surface & assay development, analysis and application in diagnostics
10.34 - 11.00	Coffee Break			

Short Talks				
11.00 - 11.07	L09	Univ.-Prof. Dr. Michaela Velikay-Parel	Medical University of Graz - Artificial Vision Center	Artificial Vision Center
11.07 - 11.14	L10	Andrew Moore	IMI Intelligent Medical Implants AG	Learning Retinal Implants
11.14 - 11.21	L11	DI Manfred Bodenlenz	JOANNEUM RESEARCH GmbH, Medical Technologies (MSG)	PROBES & SYSTEMS FOR IN VIVO DRUG TESTING: Novel approach for clinical studies of the pharmacokinetics, pharmacodynamics and the skin penetration of drugs
11.21 - 11.28	L12	Martin Hajnsek	Roche Diagnostics Graz GmbH	Sensor Platform for Continuous Glucose Monitoring
11.28 - 11.35	L13	Dr. Katharina Schallmoser	Medical University of Graz - Stem Cell Research	Animal serum free propagation of human multipotent mesenchymal stromal cells for clinical application
11.35 - 11.42	L14	Univ.-Prof. Dr. Johannes Khinast	TU Graz Institute RNS	Development of a Pharmaceutical Engineering Center in Styria
11.42 - 11.49	L15	Dr. Peter Hecht	Oridis Biomed Forschungs- und Entwicklungs GmbH	Setting standards for Biomarkers
11.49 - 11.56	L16	Univ.-Prof. Dr. Anton Glieder	Research Centre Applied Biocatalysis GmbH	Colaborative research between industry and academia in industrial biotechnology
11.56 - 12.03	L17	Dr. Ylva Huber	FFG - Austrian Res. Prom. Agency, Div. of Europ. & Intern. Programmes	European Funding Opportunities for Innovative Science
12.03 - 12.10	L18	Mag. MBA Angelika Reichl	HÄMOSAN Life Science Services GmbH	We offer cleanroom capacity for training and small scale GMP production + management support and training in English
12.10 - 12.17	L19	Oliver Bernecker	e-nnovation IT Systeme GmbH	e-nalyse Business Intelligent for clinical Study
12.17 - 13.15	Lunch break			
13.15 - 14.00	Poster Presentation			
14.00 - 18.00	Brokerage Event			
17.00 - 18.30	Partnering Day Cocktail & Snacks			

Posters

Molecular Biology / Biochemistry / Pharmacology

P01	Dr. Heimo Strohmaier	Medical University of Graz, Center for medical research (ZMF I)	Use of Special Laboratory Infrastructure and of Flow Cytometry in Modern Biomedical Research
P02	Dr. Alexis Zrimec	Institute of Physical Biology	Bioagents and Microbial Communities - Molecular Detection and Characterisation
P03	Gerhard Hofer	QIAGEN GmbH	QIAcube
P04	Dr. Christian Guelly	Medical University of Graz, Center for medical research (ZMF I)	The core-facility molecular biology is a provider of molecular biology research techniques like full-genome microarrays and mutation analysis
P05	Dr. Birgit Ebner	Medical University of Graz, Center for medical research (ZMF I)	novel technologies and services
P06	Aleš Goropevšek	University of Maribor	Monitoring intracellular signalling pathways in subsets of immune cells at the single cell level
P07	Dr. Ruth Birner-Gruenberger	Medical University of Graz, Center for medical research (ZMF I)	Our core facility provides know-how and infrastructure for proteomic analysis.
P08	Dr. Harald Köfeler	Medical University of Graz, Center for medical research (ZMF I)	Core Facility for Mass Spectrometry & Proteomics

Microbiology / Cell Biology / Histology

P09	Nadja Noormofidi	Institute for Chemistry and Technology of Organic Materials, TU Graz	Synthesis of antimicrobial polymers optimized for blending with commodity materials.
P10	Dipl. Ing. Donat Elsener	REMP AG	Establishing Biobanking facilities and SOPs
P11	Walter Chingwaru	University of Maribor	Health benefits of Tylosema (marama beans) and value added products to niche markets (Southern Africa)

Imaging

P12	Univ.-Prof. Dr. Horst Bischof	Graz University of Technology - Inst. for Computer Graphics and Vision	Medical Visual Information (Computer Vision and Graphics)
P13	Yurii Babich	Centre of diomedical electroengineering	Electrodynamic Introspecty (EI)

IT			
P14	Dr. Günter Schreier	Austrian Research Centers GmbH - ARC, Biomedical Engineering / eHealth	Web-based IT platform for Biomedical/Translational research
P15	Oliver Bernecker	e-nnovation IT Systeme GmbH	e-nalyse Business Intelligent for clinical Study
P16	DI Michael Kalkusch	Graz University of Technology - Inst. for Computer Graphics and Vision	IT Solutions for Personalized Medicine, Imaging and Biobanking
Pharmaceuticals/ Diagnostics			
P17	Barna Peitl	University of Debrecen	The aim of Sensocrine Pharma Ltd, a Specialty Pharma Co is to renew generic drugs for the treatment of diabetes (type 2 diabetes & obesity).
Services			
P18	Mag. Bernhard Weber	Science Park Graz	Business incubator for academic spin-offs
P19	Dr. Frank Sinner	BioNanoNet Forschungsgesellschaft mbH	Development and coordination of (applied) research projects
P20	Mag., MBA Angelika Reichl	HÄMOSAN Life Science Services GmbH	We offer cleanroom capacity for training and small scale GMP production + management support and training in English
P21	M.Sc Alexander Hofmeister	Medical University of Graz, Center for medical research (ZMF I)	preClinical Imaging, new service at the ZMF I
Medical Technology			
P22	Elke Muster	CNSystems Medizintechnik GmbH	The strength and core competence of CNSystems is the development of new non-invasive medical products like the Task Force® Monitor
P23	Dr. Werner Regittnig	Medical University of Graz - Dep. of Int. Med. - Diabetes Group	Novel Glucose-Controlled Insulin Delivery System for the Treatment of Type 1 Diabetes
P24	Martin Hajnssek	Roche Diagnostics Graz GmbH	sensor platform for continuous glucose monitoring

Further Topics to be discussed...

Dr. Heidi Schmitt	Medical University of Graz, Research Management	Research Management - Technology Transfer
Dr. Margit Lachmann	Medical University of Graz, Research Management	Center for Transfer of Knowledge and Technology in Medicine (ZMF III) - Looking for Partners and Tenants
Irmelin Kütke	Medical University of Graz, Research Management	Fundraising and Corporate Social Responsibility
Dr. Sándor Erdő	Erdő Pharma Kft (Ltd.)	Expert advisory and tailor-made services in biomedical research and development, business development, licensing and regulatory issues
Mag. Gerald Fasching	SFG Steirische Wirtschaftsförderung	sfg offers for production and service companies a wide range of support possibilities
Univ.-Doz. Dr. Bernhard Fischer	Biotechnology Consulting	Preclinical and clinical development of medicines & medical devices. Chemical compounds, biotechnology-derived molecules, gene- & cell- therapy.
Dr. Eva-Maria Gillesberger	Clusterland Oberösterreich GmbH - Gesundheitscluste	Clusterland Upper Austria, Health Technology Cluster
Mag. Andrea Groselj-Strele	Medical University of Graz, Center for medical research	Biostatistics
MSc Peter Beck	Joanneum Research, Health Management, Medical Informatics (MSG)	Information systems for clinical and administrative processes and project evaluation in health care
Univ.-Doz. Dr. Andrea Siebenhofer	Medical University of Graz - Dept. of Int. Med. - EBM Review Center	Creation of systematic reviews on a number of different medical topics using a validated evidence based medicine tool.
Dr. Gudrun Schmidt-Gann	Ludwig Boltzmann Institute for Experimental and Clinical Traumatology	Preclinical Models
Ing. Karl Rößl	Siemens AG Österreich - Medical Solutions	Molecular Imaging and Molecular Medicine - Clinical and Preclinical Aspects
Dipl. Ing. Simon Grasser	CTR Carinthian Tech Research AG	Spectral Imaging for medical system, diagnostic and/or screening
Priv.-Doz. Dr.med. Dr.rer.nat. Zeno Földes-Papp	Medical University of Graz, Department of Internal Medicine	Fluorescence fluctuation spectroscopic and imaging approaches to the study of single molecules in solution and within live cells
Univ.-Prof. Dr. Harald Kessler	Medical University of Graz - Institute of Hygiene	Molecular Diagnostics
Brigitte Tschuden	QIAGEN GmbH	Sample and Assay Technologies
Univ.-Prof. DI DDr. Gerhard Litscher	Medical University of Graz - RU of Biomed. Eng. in Anesth. & Int. Care	High-Tech Acupuncture®
Dr. Abdulrasagh Aziz	All Via Photonics (Science Park Graz)	

Dr. Eberhard Pirich	Bionorica research GmbH	Phytoneering
Dr. Michael Nader	IASON GmbH	Development and Evaluation of new radiopharmaceuticals for Positron Emission Tomography (PET)- Provision of PET- tracer as research tool in studies
Dr. Georg Casari	Oridis Biomed Forschungs- und Entwicklungs GmbH	Biomarkers – Novel discoveries and clinical validation
Wolfgang Senne	Oridis Biomed Forschungs- und Entwicklungs GmbH	Biomarkers – Novel discoveries and clinical validation
Christoph Reschreiter	Anagnostics Bioanalysis GmbH	hybcell - first fluorescence based microarray with kinetic measurement and flexible temperature profiles and buffer exchange
DI Michael Uhl	NEUROTH AG - Neuroth Fachinstitut Graz	
Dr. Michaela Bayer	Medical University of Graz - Res. Infrastr. & Res. Man. - Biobank	Biobanking, Quality management, Sample management
Univ.-Prof. Dr. Kurt Zatloukal	Medical University of Graz - Institute of Pathology	IT Solutions for Personalized Medicine, Imaging and Biobanking
Dr. Christian Slugovc	Institute for Chemistry and Technology of Organic Materials, TU Graz	Synthesis of antimicrobial polymers optimized for blending with commodity materials.
Dr. Kirsten Tangemann	Science Park Graz	Scientist with international R&D experience in academia and pharmaceutical companies and business know-how as CEO of an academic business incubator
Dr.med. MAS Michael Schenk	Das Kinderwunsch Institut Schenk GmbH	Gynecology, Reproduction medicine and clinical embryology: research projects and clinical studies
Drago Rudel	MKS Electronic systems Ltd.	Introducing telecare and telemedicine at home
Univ.-Prof. Dr. Andreas Tiran	Medical University of Graz, Center for Medical Research (ZMF)	Center for medical research (ZMF I)
Ing. Josef Kellner	Medical University of Graz- Inst. of Physiology- Physiol.Chemistry Group	Sample Treatment and Preparation Technologies
Ing. Wolfgang Gruber	Siemens AG Österreich - Medical Solutions	Molecular Imaging and Molecular Medicine - Clinical and Preclinical Aspects
Mag. Daniela Rosenauer	Siemens AG Österreich - Medical Solutions	Molecular Imaging and Molecular Medicine - Clinical and Preclinical Aspects
MD,PhD Claudia Eder	Orthopaedic Hospital Vienna-Speising / SpineBioLab	Tissue Engineering and Biomaterial Testing

ORGANISATION INDEX

Abteilung f. Wirtschafts- und Tourismusedwicklung - A 15 Stadt Graz - Ing. Elke Bachler	Austria
All Via Photonics (Science Park Graz) - Dr. Abdulrasagh Aziz	Austria
Lihgt-Polymer Interaction	
Anagnostics Bioanalysis GmbH - Christoph Reschreiter	Austria
hybcell - first fluorescence based microarray with kinetic measurement and flexible temperature profiles and buffer exchange	
Austrian Research Centers GmbH - ARC / Department of Bioresources - Dr Claudia Preininger	Austria
protein chips: surface & assay development, analysis and application in diagnostics	
Austrian Research Centers GmbH - ARC, Biomedical Engineering / eHealth - Dr. Günter Schreier	Austria
Web-based IT platform for Biomedical/Translational research	
BioNanoNet Forschungsgesellschaft mbH - Dr. Frank Sinner	Austria
Development and coordination of (applied) research projects	
Bionorica research GmbH - Dr. Eberhard Pirich	Austria
Phytoneering	
Biotechnology Consulting - Univ.-Doz. Dr. Bernhard Fischer	Austria
Preclinical and clinical development of medicines & medical devices. Chemical compounds, biotechnology-derived molecules, gene- & cell-therapy.	
BRG Kepler - Philipp Rössl	Austria
Centre of diomedical electroengineering - Yurii Babich	Ukraine
Electrodynamic Introscopy (EI)	
Clusterland Oberösterreich GmbH - Gesundheitscluster - Dr. Eva-Maria Gillesberger	Austria
Clusterland Upper Austria, Healthcare Cluster - a network initiative for medical technology	
CNSystems Medizintechnik AG - Elke Muster	Austria
The strength and core competence of CNSystems is the development of new non-invasive medical products like the Task Force® Monitor	
CTR Carinthian Tech Research AG - Dipl. Ing. Simon Grasser	Austria
Spectral Imaging for medical system, diagnostic and/or screening	
Das Kinderwunsch Institut Schenk GmbH - Dr.med. MAS Michael Schenk	Austria
Gynecology, Reproduction medicine and clinical embryology: research projects and clinical studies	
e-nnovation IT Systeme GmbH - Oliver Bernecker, MSc	Austria
e-nalyse Business Intelligence for clinical Study	
e-nnovation IT Systeme GmbH - DI (FH) Jürgen Prietl	Austria
e-nalyse Business Intelligence for clinical Study	
Erdö Pharma Kft (Ltd.) - Dr. Sándor Erdö	Hungary
Expert advisory and tailor-made services in biomedical research and development, business development, licensing and regulatory issues	
Faculty of Agriculture - Medecine - Maribor (Slovenia) - Olivier Rannou	Slovenia
Hepatitis E virus propagation in mammalian cell cultures	
FFG - Austrian Res. Prom. Agency, Div. of Europ. & Intern. Programmes - Dr. Ylva Huber	Austria
European Funding Opportunities for Innovative Science	
FFG - Austrian Res. Prom. Agency, Div. of Europ. & Intern. Programmes - DI Dr. MBA Sabine Herlitschka	Austria
European Funding Opportunities for Innovative Science	

Graz University of Technology - Inst. for Computer Graphics and Vision - <i>DI Marc Streit</i>	Austria
Interactive Visualization of Biomedical Data	
Graz University of Technology - Inst. for Computer Graphics and Vision - <i>Alexander Lex</i>	Austria
Visualization of Multidimensional Genetical Data with Parallel Coordinates	
Graz University of Technology - Inst. for Computer Graphics and Vision - <i>Univ.-Prof. Dr. Horst Bischof</i>	Austria
Medical Visual Information (Computer Vision and Graphics)	
Graz University of Technology - Inst. for Computer Graphics and Vision - <i>DI Michael Kalkusch</i>	Austria
IT Solutions for Personalized Medicine, Imaging and Biobanking	
HÄMOSAN Life Science Services GmbH - <i>Mag., MBA Angelika Reichl</i>	Austria
We offer cleanroom capacity for training and small scale GMP production + management support and training in English	
Human.technology Styria GmbH - <i>Dr. Robert Gfrerer</i>	Austria
IASON GmbH - <i>Dr. Michael Nader</i>	Austria
Development and Evaluation of new radiopharmaceuticals for Positron Emission Tomography (PET)- Provision of PET- tracer as research tool in studies	
IMI Intelligent Medical Implants AG - <i>Andrew Moore</i>	Switzerland
Learning Retinal Implants	
Institute for Chemistry and Technology of Organic Materials, TU Graz - <i>Nadja Noormofidi</i>	Austria
Synthesis of antimicrobial polymers optimized for blending with commodity materials.	
Institute for Chemistry and Technology of Organic Materials, TU Graz - <i>Christian Slugovc</i>	Austria
Synthesis of antimicrobial polymers optimized for blending with commodity materials.	
Institute for Technical Informatics, TU Graz - <i>Manfred Mücke</i>	Austria
Searching applications for high-speed custom computing machines in bioinformatics.	
Institute of Physical Biology - <i>Dr Alexis Zrimec</i>	Slovenia
Bioagents and Microbial Communities - Molecular Detection and Characterisation	
JOANNEUM RESEARCH Forschungsgesellschaft mbH, Laser Center Leoben - <i>Dr. Wolfgang Waldhauser</i>	Austria
We are developing functional thin coatings for biomedical applications (e.g. implants and prostheses, biosensors, biochips).	
JOANNEUM RESEARCH GmbH, Medical Technologies (MSG) - <i>DI Manfred Bodenlenz</i>	Austria
PROBES & SYSTEMS FOR IN VIVO DRUG TESTING: Novel approach for clinical studies of the pharmacokinetics, pharmacodynamics and the skin penetration of drugs	
Joanneum Research, Health Management, Medical Informatics (MSG) - <i>MSc Peter Beck</i>	Austria
Information systems for clinical and administrative processes and project evaluation in health care	
Ludwig Boltzmann Institute for Experimental and Clinical Traumatology - <i>PhD Gudrun Schmidt-Gann</i>	Austria
Preclinical Models	
Medical University of Graz - Artificial Vision Center - <i>Univ.-Prof. Dr. Michaela Velikay-Parel</i>	Austria
Artificial Vision Center	
Medical University of Graz - Dep. of Int. Med. - <i>Univ. Prof. Dr. Ernst Pilger</i>	Austria
Department of Internal Medicine	
Medical University of Graz - Dep. of Int. Med. - Cardiology - <i>Univ.-Prof. Dr. Helmut Brussee</i>	Austria
Medical University of Graz - Dep. of Int. Med. - Diabetes Group - <i>Dr. Werner Regittnig</i>	Austria
Novel Glucose-Controlled Insulin Delivery System for the Treatment of Type 1 Diabetes	
Medical University of Graz - Dep. of Int. Med. - EBM Review Center - <i>OA Dr. Karl Horvath</i>	Austria

Medical University of Graz - Department of Obstetrics and Gynaecology - Univ.-Prof. Dr. Andrea Frudinger	Austria
autologous myoblasts for incontinence	
Medical University of Graz - Department of Obstetrics and Gynaecology - MD Martina Ballon	Austria
myoblast implantation for incontinence	
Medical University of Graz - Dept. of Int. Med. - EBM Review Center - Univ.-Doz. Dr. Andrea Siebenhofer	Austria
Creation of systematic reviews on a number of different medical topics using a validated evidence based medicine tool.	
Medical University of Graz - Institute of Hygiene - Univ.-Prof. Dr. Harald Kessler	Austria
Molecular Diagnostics	
Medical University of Graz - Institute of Pathology - Univ.-Prof. Dr. Kurt Zatloukal	Austria
IT Solutions for Personalized Medicine, Imaging and Biobanking	
Medical University of Graz - Res. Infrastr. & Res. Man. - Biobank - Dr. Karine Sargsyan	Austria
NUBI - Nutrition and Bioefficacy	
Medical University of Graz - Res. Infrastr. & Res. Man. - Biobank - Dr. Michaela Bayer	Austria
Biobanking, Quality management, Sample management	
Medical University of Graz - RU of Biomed. Eng. in Anesth. & Int. Care - Univ.-Prof. DI DDr. Gerhard Litscher	Austria
High-Tech Acupuncture®	
Medical University of Graz - Stem Cell Research - Dr. Katharina Schallmoser	Austria
ANIMAL SERUM FREE PROPAGATION OF HUMAN MULTIPOTENT MESENCHYMAL STROMAL CELLS FOR CLINICAL APPLICATION	
Medical University of Graz - Stem Cell Research - Dr. Dirk Strunk	Austria
Medical University of Graz - Vice-Rector for Strategy and Innovation - Univ.-Prof. Dr. Hellmut Samonigg	Austria
Medical University of Graz, Center for medical research - Mag. Andrea Groselj-Strele	Austria
Biostatistics	
Medical University of Graz, Center for medical research (ZMF I) - Dr. Heimo Strohmaier	Austria
Use of Special Laboratory Infrastructure and of Flow Cytometry in Modern Biomedical Research	
Medical University of Graz, Center for medical research (ZMF I) - Dr. Christian Guelly	Austria
The core-facility molecular biology is a provider of molecular biology research techniques like full-genome microarrays and mutation analysis	
Medical University of Graz, Center for medical research (ZMF I) - Dr. Birgit Ebner	Austria
novel technologies and services	
Medical University of Graz, Center for medical research (ZMF I) - M.Sc Alexander Hofmeister	Austria
preClinical Imaging, new service at the ZMF I	
Medical University of Graz, Center for medical research (ZMF I) - Univ.-Prof. Dr. Andreas Tiran	Austria
Center for medical research (ZMF I)	
Medical University of Graz, Center for medical research (ZMF I) - Dr Ruth Birner-Gruenberger	Austria
Our core facility provides know-how and infrastructure for proteomic analysis.	
Medical University of Graz, Center for medical research (ZMF I) - Dr. Harald Köfeler	Austria
Core Facility for Mass Spectrometry & Proteomics	
Medical University of Graz, Department of Internal Medicine - Priv.-Doz. Dr.med. Dr.rer.nat. Zeno Földes-Papp	Austria
Fluorescence fluctuation spectroscopic and imaging approaches to the study of single molecules in solution and within live cells	

Medical University of Graz, Research Management - <i>Dr. Heidi Schmitt</i>	Austria
Research Management - Technology Transfer	
Medical University of Graz, Research Management - <i>Dr. Margit Lachmann</i>	Austria
Center for Transfer of Knowledge and Technology in Medicine (ZMF III) - Looking for Partners and Tenants	
Medical University of Graz, Research Management - <i>Irmelin Kütke</i>	Austria
Fundraising and Corporate Social Responsibility	
Medical University of Graz-Inst. of Physiology-Physiol.Chemistry Group - <i>Ing. Josef Kellner</i>	Austria
Sample Treatment and Preparation Technologies	
MKS Electronic systems Ltd. - <i>Drago Rudel</i>	Slovenia
Introducing telecare and telemedicine at home	
NEUROTH AG - Neuroth Fachinstitut Graz - <i>DI Michael Uhl</i>	Austria
Oridis Biomed Forschungs- und Entwicklungs GmbH - <i>Dr. Georg Casari</i>	Austria
Biomarkers – Novel discoveries and clinical validation	
Oridis Biomed Forschungs- und Entwicklungs GmbH - <i>Wolfgang Senne</i>	Austria
Biomarkers – Novel discoveries and clinical validation	
Oridis Biomed Forschungs- und Entwicklungs GmbH - <i>Dr. Peter Hecht</i>	Austria
Setting standards for Biomarkers	
Oridis Biomed Forschungs- und Entwicklungs GmbH - <i>Dr. Peter Amersdorfer</i>	Austria
Orthopaedic Hospital Vienna-Speising / SpineBioLab - <i>MD,PhD Claudia Eder</i>	Austria
Tissue Engineering and Biomaterial Testing	
QIAGEN GmbH - <i>Gerhard Hofer</i>	Germany
QIAcube	
QIAGEN Vertriebs GmbH - <i>Mag. Brigitte Tschuden</i>	Austria
Sample and Assay Technologies	
REMP AG - <i>Dipl. Ing. Donat Elsener</i>	Switzerland
Establishing Biobanking facilities and SOPs	
Research Centre Applied Biocatalysis GmbH - <i>Univ.-Prof. Dr. Anton Glieder</i>	Austria
Colaborative research between industry and academia in industrial biotechnology	
Roche Diagnostics Graz GmbH - <i>Martin Hajnsek</i>	Austria
sensor platform for continuous glucose monitoring	
Roche Diagnostics Graz GmbH - <i>Dr Horst Ruether</i>	Austria
Science Park Graz - <i>Mag. Bernhard Weber</i>	Austria
Business incubator for academic spin-offs	
Science Park Graz - <i>Dr. Kirsten Tangemann</i>	Austria
Scientist with international R&D experience in academia and pharmaceutical companies and business know-how as CEO of an academic business incubator	
SFG Steirische Wirtschaftsförderung - <i>Mag. Gerald Fasching</i>	Austria
sfg offers for production and service companies a wide range of support possibilities	
Siemens Corporate Technology - <i>Priv. Doz. Dr. habil. Martin Stetter</i>	Germany
IT Solutions and Databases - Learning Systems	
Siemens AG Österreich - Medical Solutions - <i>Ing. Karl Röbl</i>	Austria
Molecular Imaging and Molecular Medicine - Clinical and Preclinical Aspects	
Siemens AG Österreich - Medical Solutions - <i>Ing. Wolfgang Gruber</i>	Austria
Molecular Imaging and Molecular Medicine - Clinical and Preclinical Aspects	
Siemens AG Österreich - Medical Solutions - <i>DI Dr. Gerhard Geisswinkler</i>	Austria

Siemens AG Österreich - Medical Solutions - <i>Ing. Gerhard Zötsch</i>	Austria
Siemens AG Österreich - Medical Solutions - <i>Mag. Daniela Rosenauer</i>	Austria
Molecular Imaging and Molecular Medicine - Clinical and Preclinical Aspects	
Technology Exploitation Office, Graz University of Technology - <i>DI Dr. Alexandra Loidl</i>	Austria
TU Graz Institute RNS - <i>Johannes Khinast</i>	Austria
Development of a Pharmaceutical Engineering Center in Styria	
University of Debrecen - <i>Barna Peitl</i>	Hungary
The aim of Sensocrine Pharma Ltd, a Specialty Pharma Co is to renew generic drugs for the treatment of diabetes (type 2 diabetes & obesity).	
University of Graz - Research Services - <i>Dipl.-Ing. (FH) Michael Freidl</i>	Austria
University of Graz, Office of Research Services - <i>Dr. Manfred Hall</i>	Austria
University of Maribor - <i>Aleš Goropevšek</i>	Slovenia
Monitoring intracellular signalling pathways in subsets of immune cells at the single cell level	
University of Maribor - <i>Walter Chingwaru</i>	Slovenia
Health benefits of Tylosema (marama beans) and value added products to niche markets (Southern Africa)	

Abteilung f. Wirtschafts- und Tourismusedwicklung - A 15 Stadt Graz

Address	Stigergasse 2/1 (Mariahilfer Platz); 8020 - Graz (Austria)
Phone / Fax	T:0676-3657554
Size	250+
Organisation type	Other

Contact Person

Name	Ing. Elke Bachler
Position	Referentin
Phone / Fax	T:0676-3657554
Email	elke.bachler@stadt.graz.at

All Via Photonics (Science Park Graz)

Address	Plüddemanngasse 39/2; 8010 - Graz (Austria)
Phone / Fax	T:+43 (0) 316 873 9125
www	www.allviaphotonics.com
Size	1-10
Organisation type	Company

Contact Person

Name	Dr. Abdulrasagh Aziz
Position	Geschäftsführer
Phone / Fax	T:+43 (0) 316 873 9125
Email	a.aziz@allviaphotonics.com
www	www.allviaphotonics.com

Further Details

Short title	Light-Polymer Interaction		
Type of co-operation (Offered, Requested)	Research Project: Offered	Networking: Both	Services: Both
	Licensing:	Lecture/Poster:	
	Manufacturing:		
	Sales and Marketing:		
Areas of activity:	(Bio-)Medical Technology Diagnostics Imaging		

Project description

Research and development for non-invasive diagnostics

Type of co-operation and qualification of co-operation partner

Need for know-how in light-polymer interactions for diagnostic imaging methods
--

Short description of company/working group

All Via Photonics is a start-up company with focus on imaging methods for auto-recognition of polymers.

Anagnostics Bioanalysis GmbH

Address	Hafenstrasse 47-51; 4020 - Linz (Austria)
Phone / Fax	T:+43 732 9015 6080
Size	1-10
Organisation type	Company

Contact Person

Name	Christoph Reschreiter
Position	CEO
Phone / Fax	T:+43 732 9015 6080
Email	c.reschreiter@anagnostics.com

Further Details

Short title	hybcell - first fluorescence based microarray with kinetic measurement and flexible temperature profiles and buffer exchange		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Offered Manufacturing: Sales and Marketing: Requested	Networking: Services: Lecture/Poster:	Both Offered
Areas of activity:	Diagnostics Pharmaceutical Research Drug Targeting Instruments and equipment		

Project description

<p>Anagnostics has developed the hybcell, a new microarray format for fluorescence (chemiluminescence) measurement. The usage of this microarray is intended to be in drug discovery (protein arrays for hit validation) and diagnostics (highly parallel on chip PCR for usage in infectious disease diagnostics) .</p> <p>We focus on the development and provision of the fully-automated system itself (consumable and device) and intend to broaden our market scope by joint development and marketing for specific fields. We seek partners serving the market already and having the desire to use cutting-edge microarray technology in diagnostics.</p>

Type of co-operation and qualification of co-operation partner

Market access in the fields of drug discovery or diagnostics (protein or DNA diagnostics), need to implement multi-analyte assays and open minded approach to new technology.

Short description of company/working group

Anagnostics was founded beginning of 2005 and is now about to enter the market of drug discovery with its novel technology. Currently we employ five people (with upwards trend). Our companys philosophy is to concentrate on our strenghts of systems development, development of assay methodology and quality controlled production. We have been and are very open to cooperations which bring mutual benefit. (www.anagnostics.com)

Austrian Research Centers GmbH - ARC / Department of Bioresources

Address	2444 - Seibersdorf bei Wien (Austria)
Phone / Fax	T:+43 50550 3527 / F:+43 50550 3666
www	www.arcs.ac.at, www.bioresources.at
Size	250+
Organisation type	Research Organisation

Contact Person

Name	Dr. Claudia Preininger
Position	Project leader
Phone / Fax	T:+43 50550 3527 / F:+43 50550 3666
Email	claudia.preininger@arcs.ac.at
www	www.arcs.ac.at, www.bioresources.at

Further Details

Short title	protein chips: surface & assay development, analysis and application in diagnostics		
Type of co-operation (Offered, Requested)	Research Project: Both Licensing: Both Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster: L08	
Areas of activity:	Diagnostics Nanotechnology		

Project description

At the Department of Bioresources functional biochip surfaces as well as protein assays are developed. The department is well-equipped to successfully run all processes involved in development, production, optimization and validation of biochips: The core chip facility consists of a high-throughput contact spotter equipped with 48 TeleChem pins and two fluorescence scanners, furthermore an optical profilometer and a fluorescence microscope. Laboratory equipment for UV-polymerisation, slide coating (dipcoater) and molecular biology are also available.

The focus in surface chemistry is on the development of functional polymers, photopolymerizable monomers and hydrogels. The substrates used as chip materials comprise glass as well as plastic (i.e. TOPAS, ZEONEX).

Concerning assay development we currently work on a protein biomarker chip for sepsis (www.care-man.eu) and melanoma respectively. The approach is based on a multi-analyte sandwich on-chip immunoassay in serum 1:10. The major advantage of biochips over conventional biological techniques is the highly parallel, addressable, miniaturized array format which allows simultaneous detection of different targets, virtual automation and functional integration for high throughput screening. We are especially interested in related diagnostic applications and protein-protein interaction studies.

Type of co-operation and qualification of co-operation partner

We are looking for a partner for licensing our surface chemistries and for cooperation in protein chips for biomedical application, interaction studies, drug development ..

Short description of company/working group

The Austrian Research Centers GmbH - ARC is Austria's largest non-university center for applied research. 500 employees work at locations in Seibersdorf, Leoben, Ranshofen, Vienna, Graz, Dornbirn, Wiener Neustadt und Budapest. The Austrian Research Centers GmbH - ARC is certified according to ISO9001 and EN45000. Knowledge, research capabilities, services and products are provided to industrial and private customers as well as to public authorities.

The Division Health Technologies is one of four strategic divisions focusing on bio- and life sciences, environmental and security research and is structured into four business units: Biogenetics – Natural Resources, Biomedical Engineering, Life Sciences and Health Physics. The Department of Bioresources is one of three departments within the business unit Biogenetics - Natural Resources. The main working fields are molecular genetics, microbial analysis and biochip technology.

The biochip group at the Department of Bioresources has been working on the development of novel biochip surfaces and immobilization techniques in DNA and protein chips for several years. Various surface chemistries and microarray formats based on epoxy-resin, photoactivatable copolymers of vinylbenzylthiocyanate (VBT), polyurethane and poly(vinyl alcohol) have been developed and optimized for oligonucleotide and protein immobilization. Three surface chemistries have been patented. The actual focus of the research is on protein chips, especially on diagnostic biomarker chips for medical application (IP CARE-MAN, www.care-man.eu, FWF-Project Melanoma-Chip).

Austrian Research Centers GmbH - ARC, Biomedical Engineering / eHealth

Address	Reininghausstrasse 13/1; 8020 - Graz (Austria)
Phone / Fax	T:+43 316 586570 11 / F:+43 316 586570 12
www	www.arcsmed.at/eHs
Size	250+
Organisation type	Research Organisation

Contact Person

Name	Dr. Günter Schreier
Position	Head of Business Field eHealth systems
Phone / Fax	T:+43 316 586570 11 / F:+43 316 586570 12
Email	guenter.schreier@arcsmed.at
www	www.arcsmed.at/eHs

Further Details

Short title	Web-based IT platform for Biomedical/Translational research		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Offered Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Requested Offered L04 P14
Areas of activity:	Information processing & storage Services		

Project description

<p>web-based Medical Research Network, i.e., a web-based software platform to link numerous investigators in trans-institutional and interdisciplinary biomedical research activities. The platform features:</p> <ul style="list-style-type: none"> - central database - electronic data capture (EDC) - medical image management / Telemedicine - mobile access - tele/homemonitoring - interfaces to external systems like clinical information systems - bioinformatics support (genomics, transcriptomics, proteomics) - biosamples management <p>Innovative aspects / advantages: comprehensive IT platform, specifically tailored to support complex biomedical research and translational research projects (e.g. EU funded projects), from genome to phenome</p> <p>Application Domains: INFORMATION TECHNOLOGY, Information processing, information systems Comments about market applications: Example of a reference installation</p>

Type of co-operation and qualification of co-operation partner

<p>Type of partner sought: Industry, research organisation</p> <p>The specific area of activity of the partner: all organisations active in biomedical research and development, management of biomedical research projects, coordination of EU-projects</p> <p>The tasks to be performed of the partner sought: Using our IT-platform to increase the efficiency, effectiveness and quality of the partners research activities</p>
--

Short description of company/working group

The eHealth systems research department is part of the biomedical engineering division of the Austrian Research Centers GmbH - ARC. Parts of the team are located in Graz, Hall in Tirol and Vienna and focus on research and development projects in the following fields of Biomedical Informatics:

Bioinformatics
 Biosignal Processing
 Medical Research Networks
 Telemedicine
 Knowledge-based Systems

A team of engineers and scientists develops solutions for current challenges in these fields in close cooperation with patients, physicians from various specialties and scientists from partner institutions on an international level.

BioNanoNet Forschungsgesellschaft mbH

Address	Elisabethstraße 9 - 11; 8010 - Graz (Austria)
Phone / Fax	T:+43-316-876-2111 / F:+43-316-876-2104
www	www.bionanonet.at
Size	1-10
Organisation type	Company

Contact Person

Name	Dr. Frank Sinner
Position	Director
Phone / Fax	T:+43-316-876-2111 / F:+43-316-876-2104
Email	office@bionanonet.at
www	www.bionanonet.at

Further Details

Short title	Development and coordination of (applied) research projects		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Offered	
	Licensing:	Services:	L03 P19
	Manufacturing:	Lecture/Poster:	
	Sales and Marketing:		
Areas of activity:	Biotechnology Clinical Studies (Bio-)Medical Technology Diagnostics Pharmaceutical Research Molecular Biology Drug Targeting Imaging Nanotechnology Services		

Project description**NANO-HEALTH**

Nano-structured Materials for Drug Targeting, Release and Imaging

The joint research project Nano-Health, which consists up to now of thirteen single projects, aims to develop a platform of new multifunctional nanoparticles. These multifunctional nanoparticles will be employed for:

- * the non-invasive targeted delivery of active substances for the treatment of chronic diseases by different application routes, e.g. nasal, oral and pulmonary.
- * nanodiagnostics as contrast media in clinical imaging via magnetic resonance imaging (MRI), via fluorescence and via nuclear imaging by PET/SPECT.
- * nanodiagnostics for clinical applications for the early detection of atherosclerotic vascular lesions and to trace stem cells in cancer treatment
- * toxicological studies of nanostructured materials

Type of co-operation and qualification of co-operation partner

cooperation in research projects

Short description of company/working group

BioNanoNet GmbH is a networking company, bringing together numerous experts in the field of drug development. BioNanoNet comprises leading companies, university and non-university research institutions.

BioNanoNet acts as a "one stop shop" for the pharmaceutical industry aimed at establishing efficient and targeted contacts between potential clients and consortium members. By bundling expertises from leading scientists and private companies, BioNanoNet acts as a competent source for mission oriented research covering one or several aspects of the value added process of drug development. The philosophy of BioNanoNet is to facilitate transdisciplinary research by providing custom-made interdisciplinary teams to fulfil client's needs.

Bionorica research GmbH

Address	Mitterweg 25; 6020 - Innsbruck (Austria)
Phone / Fax	T:+43-512-276808-13
www	http://www.bionorica.com/
Size	11-50
Organisation type	Company

Contact Person

Name	Dr. Eberhard Pirich
Position	CEO
Phone / Fax	T:+43-512-276808-13
Email	eberhard.pirich@bionorica.at
www	http://www.bionorica.com/

Further Details

Short title	Phytoneering		
Type of co-operation (Offered, Requested)	Research Project: Requested	Networking: Services: Lecture/Poster:	
	Licensing: Manufacturing: Sales and Marketing:		
Areas of activity:	Biotechnology Clinical Studies Pharmaceutical Research		

Biotechnology Consulting

Address	Wilhelminenstr. 95/C/17; 1160 - Vienna (Austria)
Phone / Fax	T:+43-664-1432919 / F:+43-664-1477280
www	www.biotechnologyconsulting.at
Size	1-10
Organisation type	Company

Contact Person

Name	Univ.-Doz. Dr. Bernhard Fischer
Position	General Manager
Phone / Fax	T:+43-664-1432919 / F:+43-664-1477280
Email	biotechconsulting@aon.at
www	www.biotechnologyconsulting.at

Further Details

Short title	Preclinical and clinical development of medicines & medical devices. Chemical compounds, biotechnology-derived molecules, gene- & cell-therapy.		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Both	Services: Offered
	Licensing: Both	Lecture/Poster:	
	Manufacturing: Offered		
	Sales and Marketing: Offered		
Areas of activity:	Biotechnology Clinical Studies (Bio-)Medical Technology Pharmaceutical Research Cell Biology Drug Targeting Biochemistry Nanotechnology Trans- / Im- plantation Services		

Project description

<p>BIOTECHNOLOGY CONSULTING's mission is to provide high quality and customized expertise to the biotechnology community to allow them to meet more expeditiously and efficiently the regulatory requirements necessary to obtain marketing approval and to sell products on the worldwide market.</p> <p>Biotechnology Consulting offers to its cooperation partners:</p> <ul style="list-style-type: none"> * Regulatory affairs management of the drug development process, * Planning and performance of all preclinical and clinical activities, * Toxicity, safety pharmacology & stability studies, * Pharmaceutical formulation development, * Analytical, specification & release testing development, * Quality management GLP & GMP, * Manufacturing process development at various scale, * Drug development documentation, IMPD, IND & CTA, * Project management & direct customer support, * Sourcing of venture capital and financial support, * Management of scientific advise meetings and orphan drug application, * SME declaration and contact to medicinal agencies, according to EMEA, FDA and ICH regulations. <p>Biotechnology Consulting seeks constantly licences and collaboration agreements with academic and commercial research organisations in all areas of medicinal biotechnology.</p>
--

Type of co-operation and qualification of co-operation partner

Biotechnology Consulting has best experience with collaboration partners both from basic academic research and biotech industry. While the collaboration partner has excellent knowledge in the scientific field, Biotechnology Consulting offers the translation of discoveries into applicable products and technologies according to international regulations.

Short description of company/working group

Biotechnology Consulting is a regulatory affairs & drug development company that assists innovative biotechnology and pharmaceutical companies as well as academic research units to analyze, determine and implement the most timely, cost-effective and efficient strategies to develop a molecule from discovery through the regulatory maze to the market. Based on a thorough understanding of biotechnology and pharmaceutical sciences as well as international regulations, Biotechnology Consulting forges innovative development plans, pioneers effective regulatory strategies and provides high quality and customized expertise to its customers to allow them to perform development, preclinical and clinical studies according to national and international - ICH, FDA, EMEA - regulations. Biotechnology Consulting has first-hand biotechnology and regulatory expertise in areas as diverse as microbial and tissue culture recombinant products, biopharmaceuticals, generic products, synthetic compounds, gene and anti-sense therapy products, as well as advanced therapy (tissue engineering) products. Biotechnology Consulting offers to its customers a portfolio to carry out toxicity studies, safety pharmacology studies, mutagenicity and locale tolerance studies, pre- and formulation studies, stability studies, assay and specification development, GMP manufacture of molecules and dosage forms and clinical studies. Biotechnology Consulting assist you in the creation of innovative Business Plans, in the sourcing of Venture Capital, and drug development documentation according to international regulations.

BRG Kepler

Address	Keplerstraße 1; 8020 - Graz (Austria)
Phone / Fax	T:++43-664/8953210
Size	51-250
Organisation type	Other

Contact Person

Name	Philipp Rössl
Position	student
Phone / Fax	T:++43-664/8953210
Email	proessl.brgkepler@gmx.at

Centre of diomedical electroengineering

Address	Kurska 12A r.38; 3049 - Kiev (Ukraine)
Phone / Fax	T:(+380 44) 2453631 / F:(+380 44) 2453631
Size	11-50
Organisation type	Research Organisation

Contact Person

Name	Yurii Babich
Position	Sci director
Phone / Fax	T:(+380 44) 2453631 / F:(+380 44) 2453631
Email	babich@ua.fm

Further Details

Short title	Electrodynamic Introscopy (EI)		
Type of co-operation (Offered, Requested)	Research Project: Both Licensing: Both Manufacturing: Both Sales and Marketing: Both	Networking: Both Services: Both Lecture/Poster: L06 P13	
Areas of activity:	(Bio-)Medical Technology Diagnostics Instruments and equipment Imaging Nanotechnology		

Project description

EI is a novel functional imaging modality, which enables unique ability to visualize in vivo non-invasively (extremely low-intensive electromagnetic fields are used) dynamics of integral electrobiochemical parameters at tissue, cellular and sub-cellular levels in norm and pathology. The EI scanner can be adapted both for 3/4D dermal/transdermal and endoscopic applications. An existing portable experimental setup is designed mainly for the skin multiparameter electrophysiological imaging with spatial resolution

Type of co-operation and qualification of co-operation partner

Investements. Joint research projects. Scientific collaboration, specifically wed like to identify our discoveriries with conventional imaging modalities like< e.g., spectral in vivo confocal imaging, PET, MRI.r

Short description of company/working group

We are author research non-commercial laboratoty

Clusterland Oberösterreich GmbH - Gesundheitscluster

Address	Hafenstrasse 47-51; 4020 - Linz (Austria)
Phone / Fax	T:0732/79810-5155 / F:0732/79810-5150
www	http://www.gesundheits-cluster.at
Size	11-50
Organisation type	Company

Contact Person

Name	Dr. Eva-Maria Gillesberger
Position	Projektmanagerin Gesundheits-Cluster
Phone / Fax	T:0732/79810-5155 / F:0732/79810-5150
Email	eva.gillesberger@clusterland.at
www	http://www.gesundheits-cluster.at

Further Details

Short title	Clusterland Upper Austria, Healthcare Cluster - a network initiative for medical technology		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Offered Offered

Areas of activity: Information processing & storage
(Bio-)Medical Technology
Diagnostics
Instruments and equipment, Services

Short description of company/working group

„Networking“ – the secret of successful businesses! Partnering with the Healthcare Cluster (HC) ensures a definite advantage for your company! The Healthcare Cluster is an industry overlapping network that veritably strengthens innovative power and international competitiveness of companies in the medical technology industry.

A clear focus for your business!

The main focus of the cluster's activities is to strengthen and expand the medical technology sector as well as the cooperation of companies and health care facilities.

The long-term goal of the HC: To establish Upper Austria as the medical technology location.

The prerequisites for this look very promising. Medical technology is an economic sector with enormous future potential and impressive growth rates of up to seven percent. Hence, it also offers a chance for corporations from other economic areas, such as the car, mechatronics, and plastics industry. The HC aims to support these companies by facilitating access to the medical technology sector in order to enable development of a secure second main pillar.

And this is how your business will benefit from the HC services:

KNOW-HOW!

- >Information about the industry: Edited, up-to-date, focussed
- >Market transparency – technological expertise
- >Monthly newsletter: Important information straight on your PC
- >Our homepage as a platform for your company
- >Articles about your company in our journal (Edition: 14,500 units)

COOPERATION!

- >Support of innovation projects
- >Support of your search for a suitable business partner
- >Support of application admission
- >Rapid and uncomplicated access to subsidies
- ...on a regional, national, and European level

HC PARTNERSHIP PROVIDES BENEFITS!

- >Improved conditions at all offers
- >Media support for your company
- >Event participation free of charge
- >Special conditions for advertising
- >Data set entry in our service catalogue free of charge

CNSystems Medizintechnik AG

Address	Reinigungsstrasse 13; 8020 - Graz (Austria)
Phone / Fax	T:+43 316 723456-52 / F:+43 316 723456-2
www	www.cnsystems.at
Size	11-50
Organisation type	Company

Contact Person

Name	Elke Muster
Position	Management Assistant
Phone / Fax	T:+43 316 723456-52 / F:+43 316 723456-2
Email	elke.muster@cnsystems.at
www	www.cnsystems.at

Further Details

Short title	The strength and core competence of CNSystems is the development of new non-invasive medical products like the Task Force® Monitor		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Both	Services: Both
	Licensing:	Lecture/Poster: P22	
	Manufacturing:		
	Sales and Marketing: Both		
Areas of activity:	Clinical Studies (Bio-)Medical Technology Diagnostics		

Project description

<p>The Task Force® Monitor is a non-invasive, diagnosis aiding monitoring system that records all relevant haemodynamic parameters, including heart rate (HR), stroke volume (SV), cardiac output (CO), blood pressure (BP), total peripheral resistance (TPRI), baroreceptor reflex sensitivity (BRRS), vagal and sympathetic tone etc., without discomfort for the patient. All parameters are recorded in real time and beat-to-beat and are displayed both as signals and numeric values.</p> <p>The system combines four measuring methods:</p> <ul style="list-style-type: none"> - continuous (beat-to-beat) blood pressure measurement - impedance cardiography (for SV and CO measurement) - high resolution 3-channel-ECG display (6-channel display) - oscillometric blood pressure measurement
--

Type of co-operation and qualification of co-operation partner

<p>Type of co-operation sought:</p> <ul style="list-style-type: none"> - Technical co-operation - Joint Venture agreement - Research co- operation <p>Type of partner sought: research organisation</p>
--

Short description of company/working group

<p>The company slogan "The Brain and Heart Company" embodies our idea that the brain achieves top technical performances and the heart strives for success.</p> <p>CNSystems Medizintechnik GmbH was founded in 1998 as a spin-off of the Hospital Barmherzige Brüder (Teaching Hospital of the Medical University) and the Technical University in Graz. The company is still running different research projects in close collaboration with both universities and other institutions.</p> <p>The idea</p> <p>Due to increasing medical demand, combined with new technical and scientific facilities, Prof. Falko Skrabal, Medical Director of the Hospital Barmherzige Brüder in Graz, conceived the idea to develop a completely new, non-invasive, diagnosis aiding monitoring system. This system measures all relevant haemodynamic parameters in real time and provides revolutionary insight into the regulation mechanisms of the autonomic nervous system.</p> <p>Both universities in Graz worked toward the realisation of this idea as the focus of many doctor and master theses. About five years later, a system was developed, combining existing devices: the first Task Force® Monitor (prototype).</p> <p>Jürgen Fortin, one of the founders of CNSystems, finally completed together with his staff the development of this new</p>

measurement instrument with accompanying software. In 1999, the Task Force® Monitor achieved the European certification (CE0408).

success

The public recognition of CNSystems in the past was very high – not only due to awards like “Red Herring Top 100” and the Austrian National Award of innovation, but also because of our customers like NASA, the International Space Station and renowned hospitals like Mayo Clinic, Charité Berlin, Karolinska Stockholm and so on.

During the first year in business, the number of staff members grew from three to 12 employees, but the growing demand on the market necessitated a further expansion to 40 employees. The company sells its products all over the world.

CTR Carinthian Tech Research AG

Address	Europastr. 4/1; 9524 - Villach / St. Magdalen (Austria)
Phone / Fax	T:+43-(0)4242-56300 / F:+43-(0)4242-56300-400
www	www.ctr.at
Size	11-50
Organisation type	Research Organisation

Contact Person

Name	Dipl. Ing. Simon Grasser
Position	Manager Sales and Finance
Phone / Fax	T:+43-(0)4242-56300 / F:+43-(0)4242-56300-400
Email	simon.grasser@ctr.at
www	www.ctr.at

Further Details

Short title	Spectral Imaging for medical system, diagnostic and/or screening		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Both	Services: Both
	Licensing:	Lecture/Poster:	
	Manufacturing:		
	Sales and Marketing:		
Areas of activity:	Clinical Studies (Bio-)Medical Technology Diagnostics Pharmaceutical Research Cell Biology Imaging Other		

Project description

Spectral imaging, or imaging spectroscopy, combines the advantages of traditional machine vision with the potentials of optical spectroscopy. Spectral imaging sensors can acquire hyper-spectral images, images with an additional spectral dimension, providing not only the brightness or colour but an entire spectrum for each pixel. This allows acquiring images containing valuable information about the molecular composition or the condition of biological tissue.

CTR has developed an in-vivo, non-invasive diagnostic device for the detection of skin cancer. The device is currently validated in two clinical studies with success.

- adaptation/extension to endoscopic measurements for e.g. detection colon carcinoma, upper and lower gastrointestinal tract, etc.

- assessment of allergies or cosmetic products with non-invasive macro- or microscopis imaging

For clinical screening systems spectral imaging could speed up experiments by increasing the number of simultaneously detectable fluorophores. Currently only two or three fluorophores can be detected reliably during one experiment (well). With spectral imaging up to 8 or more fluorophores can be detected in one experiment well by using Spectral Unmixing, PCA, ICA, or other unmixing methods. The development of clinical screening equipment or devices for cell biology analysis using spectral imaging during a R&D project would be of great interest to CTR.

Type of co-operation and qualification of co-operation partner

Industrial partners who are interested in R&D projects for the development of new products based on spectral imaging e.g. in-vivo non-invasive image-based medical diagnosis system, microscopic multispectral imaging and analysis devices, clinical screening for multifluorophoric experiments, endoscopic imaging systems for acquisition of multispectral images, etc.

Short description of company/working group

CTR is a non-university research and development centre in the south of Austria focusing on sensors, optics and microsystems technology.

The CTR team strives to enhance optical measurement techniques by developing new sensor systems (spectral information, laser technology and microsystems). Their advantages in practical applications: greater reliability, smaller designs and thus higher profitability in production. Spectral imaging opens up a wide range of applications for scientists and engineers in medicine, agriculture, the processing industry, recycling, chemistry and forensic medicine.

In-depth expertise at every stage of implementation - from feasibility studies, conception and design through prototyping and testing - also using simulation techniques - to finished system and product solutions.

Our competence:

- * Non-contact analysis of foodstuffs (quality, degree of ripeness, pests or mould)
- * Quality control in agricultural products (e.g. seeds, grains, plants)
- * Selection of solids according to visual and chemical criteria
- * Detection of spatially resolved concentrations (e.g. in pharmaceuticals)
- * Automatic material classification (e.g. sorting plastics)
- * Expertise in sensor & systems engineering
- * Development of user-friendly software
- * Know-how in the field of efficient algorithms

Das Kinderwunsch Institut Schenk GmbH

Address	Am Sendergrund 11; 8143 - Dobl (Austria)
Phone / Fax	T:++43/3136/55 111 / F:++43/3136/55 111-15
www	www.kinderwunsch-institut.at
Size	11-50
Organisation type	Company

Contact Person

Name	Dr.med. MAS Michael Schenk
Position	Medical Director
Phone / Fax	T:++43/3136/55 111 / F:++43/3136/55 111-15
Email	office@kinderwunsch-institut.at
www	www.kinderwunsch-institut.at

Further Details

Short title	Gynecology, Reproduction medicine and clinical embryology: research projects and clinical studies		
Type of co-operation (Offered, Requested)	Research Project: Requested	Networking: Requested	Services: Requested
	Licensing:	Lecture/Poster:	
	Manufacturing:		
	Sales and Marketing:		
Areas of activity:	Clinical Studies Cell Biology Other		

Project description

As a clinic for reproduction medicine we use all common techniques in ART like IVF, ICSI, sperm preparation, cryopreservation,...

We are always interested to find new diagnostic methods and/or new/better therapies to increase the success rate of pregnancies.

Type of co-operation and qualification of co-operation partner

Request for co-operation in research projects and clinical studies in the topics of reproduction medicine (therapy, diagnosis, IVF-techniques,...)

Short description of company/working group

The Kinderwunsch Institut is an independent clinic for Reproduction medicine and clinical embryology. Here patients find help with reproductive disorders and support to fulfill their wish of an own child.

On the other hand we co-operate with various partners (company, university) in research projects and international clinical studies.

A professional, experienced team, customized, state of the art technique and high level quality standards (DIN EN ISO 9001/2000 and GxP) helps us to bring the best results for our patients and project partners.

e-nnovation IT Systeme GmbH

Address	Göstingerstr. 213; 8051 - Graz (Austria)
Phone / Fax	T:+43 (0) 316 / 67 82 64 / F:+43 (0) 316 / 67 82 64 64
www	www.e-nnovation.at
Size	11-50
Organisation type	Company

Contact Person

Name	Oliver Bernecker, MSc
Position	CEO
Phone / Fax	T:+43 (0) 316 / 67 82 64 / F:+43 (0) 316 / 67 82 64 64
Email	o.bernecker@e-nnovation.at
www	www.e-nnovation.at

Contact Person

Name	DI (FH) Jürgen Prietl
Position	eHealth Consultant
Phone / Fax	T:+43 (0) 316 / 67 82 64 / F:+43 (0) 316 / 67 82 64 64
Email	j.prietl@e-nnovation.at
www	www.e-nnovation.at

Further Details

Short title	e-nalyse Business Intelligence for clinical Study		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Both	Services: Both
	Licensing: Both	Lecture/Poster: L19 P15	
	Manufacturing: Both		
	Sales and Marketing: Both		
Areas of activity:	Information processing & storage Clinical Studies Diagnostics Pharmaceutical Research Cell Biology		

Drug Targeting
Instruments and equipment
Services
Other

Project description

The project, „e-nalyse“ requested from the clinical institute of medical and chemical laboratory diagnostic (Medical University of Graz), was developed by e-nnovation IT Systems and presents a pioneering solution in the business of area medical data processing, documenting and data saving. This solution enables a supporting of all central processes within broad epidemiologically studies. Booking, documenting, automatically networked data communication to other external CIS and LIS, the data migration and archiving, the full automatically report transfer with an EHR-compliant communication are only some of the e-nnovation features.

Type of co-operation and qualification of co-operation partner

We are open to any customer who wants to engage in a working partnership with us. We expect to work together in eHealth and eGovernment based topics an in best case in combination of both.

Short description of company/working group

The company works under the guidance of managing director Oliver Bernecker, MSc, on the development, introduction and integration of high-innovative IT-total conceptions for the health industry and/or health service offerers as well as to introduce and combine complex eGovernment applications and their integration in public municipalities and existing healthcare structures.

Projects:

- * e-nalyse
- * cost-controll-software for the usage in most medical areas (e.g. laboratory...)
- * Wireless Medical-Project

... to hear more ... contact us or visit www.e-nnovation.at

Erdö Pharma Kft (Ltd.)

Address	Szüret u. 4/B; 2092 - Budakeszi (Hungary)
Phone / Fax	T:+36 23 454 900
www	www.erdopharma.hu
Size	1-10
Organisation type	Company

Contact Person

Name	Dr. Sándor Erdö
Position	managing director
Phone / Fax	T:+36 23 454 900
Email	sandor.erdo@erdopharma.hu
www	www.erdopharma.hu

Further Details

Short title	Expert advisory and tailor-made services in biomedical research and development, business development, licensing and regulatory issues			
Type of co-operation (Offered, Requested)	Research Project:	Both	Networking:	Both
	Licensing:	Both	Services:	Offered
	Manufacturing:		Lecture/Poster:	
	Sales and Marketing:			

Areas of activity:	Biotechnology Clinical Studies (Bio-)Medical Technology Diagnostics Pharmaceutical Research Molecular Biology Cell Biology Drug Targeting Instruments and equipment Biochemistry Imaging Nanotechnology Services
--------------------	--

Project description

We offer expert advisory and a wide range of tailor-made services in the field of biomedical research and development. Our services include, but are not restricted to the

- preparation, reviewing or evaluation of R&D documentation, business plans
- expert advisory in product development, intellectual property, project financing and regulatory issues,
- organisation and management of clinical trials,
- finding licence partners and investors

We do welcome companies and institutions seeking permanent representation or occasional, e.g., regulatory services in Hungary.

Type of co-operation and qualification of co-operation partner

- Innovative SMEs, biomedical RTD companies, and individuals seeking expert services
- All players of biomedical innovation chain with a specific interest in services from/in Hungary

Short description of company/working group

Erdö Pharma is a private consulting company offering a wide range of tailor-made services and solutions for innovative SMEs and individuals in the pharmaceutical and biomedical sectors. The company was established in 1998 and has been involved in more than 20 successful projects and deals world-wide.

Faculty of Agriculture - Medicine - Maribor (Slovenia)

Address	Vrbanska 30; 0 - Maribor (Slovenia)
Phone / Fax	T:+386 2 330 58 72
Size	250+
Organisation type	University

Contact Person

Name	Olivier Rannou
Position	Research Assistant
Phone / Fax	T:+386 2 330 58 72
Email	olivierket@aol.com

Further Details

Short title	Hepatitis E virus propagation in mammalian cell cultures	
Type of co-operation	Research Project:	Networking:
(Offered, Requested)	Licensing:	Services:
	Manufacturing:	Lecture/Poster:
	Sales and Marketing:	

Areas of activity:	Biotechnology (Bio-)Medical Technology Molecular Biology Cell Biology Biochemistry
--------------------	--

FFG - Austrian Res. Prom. Agency, Div. of Europ. & Intern. Programmes

Address	Sensengasse 1; 1090 - Wien (Austria)
Phone / Fax	T:+43 5 77 55 4102 / F:+43 5 77 44 94011
www	www.ffg.at
Size	51-250
Organisation type	Company

Contact Person

Name	Dr. Ylva Huber
Position	Information Officer, Health NCP
Phone / Fax	T:+43 5 77 55 4102 / F:+43 5 77 44 94011
Email	ylva.huber@ffg.at
www	www.ffg.at

Contact Person

Name	DI Dr. MBA Sabine Herlitschka
Position	Director
Phone / Fax	T:+43 (0)5 7755 - 4001
Email	sabine.herlitschka@ffg.at
www	www.ffg.at

Further Details

Short title	European Funding Opportunities for Innovative Science		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Offered Offered L17
Areas of activity:	Services		

Project description

Customized advice & assistance is provided on questions concerning Research and Innovation activities, particularly the EU multi-annual Framework Programme, including:

- How can I obtain funding for my research project idea?
- How does my project ideally fit into the 7th EU Framework Programme (FP7)?
- What features of FP7 are of particular interest for me?
- How can I improve my project proposal?
- What funding opportunities apart from FP7 may be suitable for my research and innovation activities?
- How can I find cooperation partners with the expertise I need?
- How can I enlarge my network of R&D contacts and raise my international visibility?
- (...)

Type of co-operation and qualification of co-operation partner

In order to ensure optimal efficiency of the meetings, it would be helpful to receive information on:

- your project proposal or your ideas for future R&D projects and innovation activities
- your research area/expertise
- your expectations from potential cooperation partners (required expertise)
- your previous experience with national and/or international cooperation in R&D

Short description of company/working group

Core activities of FFG/EIP:

- Providing information on EU & international RTD for > 30.000 individuals from 14.000 organisations in Austria
- Finding complementary partners for R&D projects in Austria and abroad
- Providing advice and coaching for proposers
- Checking project idea vs. Programme and Call
- Advising for all evaluation criteria, legal and financial aspects of R&D projects within the European Framework Programmes
- Following an enlargement and internationalisation strategy

Graz University of Technology - Inst. for Computer Graphics and Vision

Address	Inffeldgasse 16/II; 8010 - Graz (Austria)
Phone / Fax	T:+43 (316) 873 - 5014
www	www.icg.tugraz.at
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Prof. Dr. Horst Bischof
Position	head
Phone / Fax	T:+43 (316) 873 - 5014
Email	bischof@icg.tu-graz.ac.at
www	www.icg.tugraz.at

Further Details

Short title	Medical Visual Information (Computer Vision and Graphics)		
Type of co-operation (Offered, Requested)	Research Project: Offered	Networking:	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	P12
	Sales and Marketing:		
Areas of activity:	Information processing & storage Imaging		

Project description

The Institute for Computer Graphics and Vision (TU Graz) is involved in several projects dealing with medical images analysis and interactive visualization systems like computeraided surgical planning or guidance of minimally invasive procedures. Based on our broad expertise, we develop one stop shop solutions requiring (automated) analysis and visualization of medical data. In particular, our research is focused on image segmentation, registration, 3D visualization and 3D interaction. Various research project will be presented at the meeting to demonstrate the opportunities arising from modern computer vision and graphics methods in the medical field.

*By combining the fields of medical image analysis and computer graphics, a Virtual Liver Surgery Planning System (VLSPS) was developed - in cooperation with the Medical University of Graz - that supports the radiologists work and provides information to the surgeons. A VLSPS consists of image analysis and image visualization parts. In the case of liver resection, the image analysis identifies the liver, liver tumors, and defines liver segments. Interactive visualization facilitates the virtual liver resection planning. The achievable improvements associated with the use of VLSPS include objective, reproducible, and operator-independent results regarding segmentation and volume measurements, as well as exact identification of the involved liver segments. This approach yields an increased transparency and documents the surgical planning decisions.

* The EU project ARISER aims at developing new solutions for using Augmented Reality in minimally invasive surgery. The aim is to equip a surgeon with technologically enhanced super vision. The main focus of TU-Graz in this project is to provide 3D augmented reality visualization tools, in particular augmented video endoscopy.

* Image Analysis using Active Appearance Models to quantify Rheumatoid Arthritis in X-Ray images of the hand. The AAMIR project (www.aamir.at), funded by the FWF, aims at the development of a fully automated assessment of destructions caused to the bones by rheumatoid arthritis (RA), an incurable disease affecting predominantly the peripheral joints. RA is one of the leading causes for disability among persons aged 15 and older. The accurate and precise quantification of the disease progression is crucial for successful therapy and during clinical trials. Within the scope of AAMIR, methods applicable in clinical practice are developed and the potential and possible extensions to the active appearance model (AAM) concept are investigated.

* In a number of projects we are developing various methods for non-rigid registration. In particular we will present an approach based on 3D extension of the shape context which has been applied to sheep lung data for assessing breathing motion.

Innovative aspects / advantages:

Robust Active Appearance Models

Non rigid Registration

Augmented and Virtual Reality

Visualization and Computer Vision in a common framework

Application Domains:

Automation/Robotics, INFORMATION TECHNOLOGY, Information processing, information systems, Medicine, health

Type of co-operation and qualification of co-operation partner

The specific area of activity of the partner:

Industry for developing products out of our developments

Academia (especially medical partners) for further development.

Short description of company/working group

The Institute for Computer Graphics and Vision (TU Graz) is involved in several projects dealing with medical images analysis and interactive visualization systems like computer-aided surgical planning or guidance of minimally invasive procedures.

Graz University of Technology - Inst. for Computer Graphics and Vision

Address	Inffeldgasse 16; 8010 - Graz (Austria)
Phone / Fax	T:+433168735073
www	http://www.icg.tugraz.at
Size	250+
Organisation type	University

Contact Person

Name	DI Michael Kalkusch
Position	Research Assistant
Phone / Fax	T:+433168735073
Email	kalkusch@icg.tugraz.at
www	http://www.icg.tugraz.at

Further Details

Short title	IT Solutions for Personalized Medicine, Imaging and Biobanking			
Type of co-operation (Offered, Requested)	Research Project:	Requested	Networking:	Requested
	Licensing:		Services:	
	Manufacturing:		Lecture/Poster:	P16
	Sales and Marketing:			
Areas of activity:	Information processing & storage Molecular Biology, Imaging			

Project description

An increasingly important aspect for medicine in the 21st century is the growing need for treatment of many diseases on the level of the individual patient and for improving the efficacy of the drug development process. Such approaches are made possible by emerging resources, such as biobanks, large repositories of biological samples linked to medical data, and information extracted from these samples, e.g. gene expression profiles, proteomic and metabolomic information. Such resources require completely new approaches with respect to the IT infrastructure which must provide sample tracking and management, access control and guaranteeing patients' anonymity, data management and information mining. Owing to the complexity of the data associated with such samples, an important aspect of such an infrastructure is to provide tools which are specifically designed to analyze and visualize extremely large, complex datasets.

Our efforts to implement one of the worlds largest biobanks at the Medical University of Graz, at the Institute of Pathology have prompted the implementation of such an IT infrastructure. Besides the issues of sample management and tracking, anonymization, prevention of patient re-identification through the concept of k-anonymization, one important aspect which is currently addressed is visual data mining, which is addressed in the GenView and VIPEM projects [www.geneview.org]. Complex and heterogeneously structured data (laboratory parameters, diagnosis, treatment and outcome, micro-array analysis data, and even images) are linked to the biobank samples and data mining within these data sets is supported by exploiting human visual capacities. Complex data are coded in glyphs to allow immediate perception of similarities or differences and which can be interactively arranged and grouped in various ways. Interactive selection and browsing of metabolic pathways and signaling pathways provide additional information revealing the biological functions. Through a close link between several input channels, which are simultaneously active, and by immediate visualization of the steps of the analysis, the expert is provided with a tool for the interactive exploration of complex data spaces. As input parameter for analysis and data mining algorithms this system employs the human capacity to grasp complex patterns and correlations and thus allows to reveal hidden structures.

Type of co-operation and qualification of co-operation partner

We are looking for partners interested in visual data mining of large micro-array data sets.

Short description of company/working group

We are developing a visual data mining framework for exploration of micro-array data and heterogeneous data.

Graz University of Technology - Inst. for Computer Graphics and Vision

Address	Inffeldgasse 16; 8010 - Graz (Austria)
Phone / Fax	T:+433168735064
www	www.icg.tugraz.at
Size	250+
Organisation type	University

Contact Person

Name	DI Marc Streit
Position	Research Assistant
Phone / Fax	T:+433168735064
Email	streit@icg.tugraz.at
www	www.icg.tugraz.at

Further Details

Short title	Interactive Visualization of Biomedical Data		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking:	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	
	Sales and Marketing:		
Areas of activity:	Information processing & storage Imaging		

Project description

Visualization of Micro Array data using multiple displays. Interactive handling of complex and high dimensional bio-medical data.

Graz University of Technology - Inst. for Computer Graphics and Vision

Address	Inffeldgasse 16/II; 8010 - Graz (Austria)
Phone / Fax	T:004369913252526
Size	250+
Organisation type	University

Contact Person

Name	Alexander Lex
Position	Research Assistant
Phone / Fax	T:004369913252526
Email	alexander.lex@student.tugraz.at

Further Details

Short title	Visualization of Multidimensional Genetical Data with Parallel Coordinates		
Type of co-operation (Offered, Requested)	Research Project: Offered	Networking:	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	
	Sales and Marketing:		
Areas of activity:	Biotechnology Information processing & storage (Bio-)Medical Technology Imaging		

Type of co-operation and qualification of co-operation partner

We are looking for partners interested in visual data mining of large micro-array data sets.

Short description of company/working group

We are developing a visual data mining framework for exploration of micro-array data and heterogeneous data.

HÄMOSAN Life Science Services GmbH

Address	Neudorf 41; 8262 - Ilz (Austria)
Phone / Fax	T:+43-(0)3385-8117 / F:+43-(0)3385-8117-44
www	www.haemosan.com
Size	1-10
Organisation type	Company

Contact Person

Name	Mag., MBA Angelika Reichl
Position	Co-ordinator
Phone / Fax	T:+43-(0)3385-8117 / F:+43-(0)3385-8117-44
Email	info@haemosan.com
www	www.haemosan.com

Further Details

Short title	We offer cleanroom capacity for training and small scale GMP production + management support and training in English		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Offered L18 P20
Areas of activity:	Services		

Project description

1 Cleanroom capacity (D-A) for training purposes on the one hand and for small scale GMP production - for example for clinical trials - on the other hand. We also offer the complete infrastructure of a training center (transport/catering/seminar facilities/accomodation/social events if required) including speakers/trainers on request
2 Management support for various R&D projects. Management training (both specific life science management and general management) in English

Type of co-operation and qualification of co-operation partner

We are open to any customer who wants to engage in a working partnership with us. In order to give quality services to our customers however, it may be necessary to learn details of the relevant project. So we expect co-operation on the basis of mutual confidentiality agreements, if necessary. For our cleanroom services we prefer partners in the fields of pharmaceutical industry and surgery.

Short description of company/working group

HÄMOSAN has developed from a producer (Bovine Serum Albumin) - 1988 - to a research service company (prion and viral safety in biological products) - 1994 onwards - to a service company - 2000 onwards. The management of substantial (also 4 EU-co-financed) research projects and the combination of entrepreneurial experience, biotech expertise, sound management skills and high social competence make the company an attractive partner.
--

Human.technology Styria GmbH

Address	Reininghausstrasse 13; 8020 - Graz (Austria)
Phone / Fax	T:+43-316-587016-0
www	www.humantechnology.at
Size	1-10
Organisation type	Company

Contact Person

Name	Dr. Robert Gfrerer
Position	CEO
Phone / Fax	T:+43-316-587016-0
Email	robert.gfrerer@humantechology.at
www	www.humantechology.at

Further Details

Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:
Areas of activity:	Services	

IASON GmbH

Address	Seilerstaette 4; 4010 - Linz (Austria)
Phone / Fax	T:0043(0)732-785-125 / F:0043(0)732785125-14
www	www.iason.at
Size	11-50
Organisation type	Company

Contact Person

Name	Dr. Michael Nader
Position	Head of Research and Development
Phone / Fax	T:0043(0)732-785-125 / F:0043(0)732785125-14
Email	michael.nader@iason.at
www	www.iason.at

Further Details

Short title	Development and Evaluation of new radiopharmaceuticals for Positron Emission Tomography (PET)- Provision of PET- tracer as research tool in studies		
Type of co-operation (Offered, Requested)	Research Project: Both Licensing: Manufacturing: Both Sales and Marketing:	Networking: Services: Both Lecture/Poster:	
Areas of activity:	Clinical Studies Diagnostics Pharmaceutical Research Molecular Biology Drug Targeting Biochemistry Imaging Services		

Project description

Positron Emission Tomography (PET) is a non-invasive imaging technology which is used for clinical routine diagnostics and as research tool in drug discovery and development. Pharmacokinetics and biodistribution of drug candidates can be non-invasively and longitudinally measured with PET after proper labelling of the drug with a positron emitter, such as F-18 or C-11, in both preclinical and clinical studies. Pharmacodynamics and therapeutic responses can be monitored by functional imaging with PET and dynamic contrast enhanced MRI, which reveals metabolic and physiological changes of target tissues towards therapies. Any drug candidate with poor pharmacokinetics and pharmacodynamics can be readily identified and eliminated earlier in the drug development process. Accurate identification of the right drug candidates will certainly eliminate unnecessary costs and facilitate the process of drug development.

In summary the development of new PET probes for the imaging of specific metabolic models in course of academic projects, the application of PET as research tool for the clarification of the metabolism of new drugs with industrial partners as well as the use of PET tracers for the measurement of metabolic response after chemo/radiation therapy would be of great interest in the cooperation with clinical partners.

Type of co-operation and qualification of co-operation partner

Type of co-operation sought:

Research Projects

Commercial realisation of scientific ideas in the area of nuclear molecular imaging

Type of partner sought:

University

Scientific centres

Industry

Specific area of activity of the partner:

Expertise in preparative organic synthesis or nuclear molecular

Task to be performed:

We are interested in projects which are focused in the development and application of molecular imaging agents (preferentially Positron Emission Tomography - PET) for oncology, neurology or cardiology.

Vice versa we are offering the design (on demand) and commercialisation of radioactive tracer. Furthermore, we are offering our "know how" as project partner of the pharmaceutical industry for the evaluation of the new pharmaceuticals (pharmacokinetics, therapy control, molecular imaging).

Short description of company/working group

IASON GmbH is the leading producer of radiopharmaceuticals used in the Positron Emission Tomography (PET) in Europe. The company has been founded in 1994 and operates 3 cyclotrons in Austria and Italy.

Research is performed in the development of new PET- radiopharmaceuticals.

IMI Intelligent Medical Implants AG

Address	Gotthardstrasse 3; 6304 - Zug (Switzerland)
Phone / Fax	T:+41 79 216 2946 / F:+41 41 7233839
www	www.intmedimplants.com
Size	11-50
Organisation type	Company

Contact Person

Name	Andrew Moore
Position	Managing Director
Phone / Fax	T:+41 79 216 2946 / F:+41 41 7233839
Email	andrew.moore@intmedimplants.com
www	www.intmedimplants.com

Further Details

Short title	Learning Retinal Implants		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking:	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	L10
	Sales and Marketing:		
Areas of activity:	(Bio-)Medical Technology Instruments and equipment Trans- / Im- plantation		

Project description

The Intelligent Retinal Implant System TM is an adaptive visual prosthesis – an artificial retina – that bridges and replaces the defective information processing function of the real retina in patients with retinal degeneration. It thus enables blind people to regain modest visual perception and a sense of orientation even in unfamiliar surroundings.

The Retinal Implant is expected to improve the quality of life of this group of patients significantly and permanently.

The learning Retinal Implant is still being studied in clinical trials and is not yet available commercially.

Type of co-operation and qualification of co-operation partner

Already cooperating with the Medical University of Graz.

Short description of company/working group

IMI Intelligent Medical Implants is a medical technology company. The goal of the company is to develop and market an intelligent retinal implant system for degenerative retinal disorders such as Retinitis Pigmentosa or Macular Degeneration and thereby make a contribution to the improvement of the quality of life of blind people. Through the combination of innovative technology from the medical device, IT and micro systems fields, a new class of active medical products has been created allowing, amongst other things, blind people to regain modest visual perception.

Institute for Chemistry and Technology of Organic Materials, TU Graz

Address	Stremayrgasse 16/1; 8010 - Graz (Austria)
Phone / Fax	T:0043 316 873 8485 / F:0043 316 873 8951
www	http://www.ictos.tugraz.at
Size	250+
Organisation type	University

Contact Person

Name	Nadja Noormofidi
Position	PhD Student
Phone / Fax	T:0043 316 873 8485 / F:0043 316 873 8951
Email	noormofidi@tugraz.at
www	http://www.ictos.tugraz.at

Contact Person

Name	Christian Slugovc
Position	Dr.
Phone / Fax	T:0043 316 873 8485 / F:0043 316 873 8951
Email	slugovc@tugraz.at
www	http://www.ictos.tugraz.at

Further Details

Short title	Synthesis of antimicrobial polymers optimized for blending with commodity materials.			
Type of co-operation (Offered, Requested)	Research Project:	Offered	Networking:	Requested
	Licensing:		Services:	
	Manufacturing:	Requested	Lecture/Poster:	P09
	Sales and Marketing:			
Areas of activity:	Biotechnology (Bio-)Medical Technology Pharmaceutical Research Cell Biology Biochemistry, Nanotechnology			

Project description

Polymers with antimicrobial activity have many advantages. Leaching of the biocides into surroundings is greatly suppressed in such materials and constitutes the major advantage over conventional biocides operating on the release of the agent. Our endeavours focus on the application of such microbicidal materials as additives for commodity materials such as poly(ethylene) (PE) or poly(styrene) (PS). By self-assembling, the functionality is guided to the surface of the material and physical properties of the commodity materials are hardly affected by the additive. Emphasis is placed on the prevention of leakage accompanied with high activity of the contact biocides. Further research involves the usage of different biocidal agents, the extension of the method towards other commodity materials and the activity against fungi.

Type of co-operation and qualification of co-operation partner

We recently issued a patent (WO 2007/045634 A2) on the copolymerisation of biocidal monomers with differently substituted co-monomers by Ring Opening Metathesis Polymerisation (ROMP) and currently exploit the IPRs in partnership with several enterprises not in the life science field.

We consider life science and in particular medical science and medical engineering as the main target group and aim to establish contact with interested parties.

We expect inputs for potential applications and exploitations and are truly interested in a joint development translating the common knowledge to a product in the market.

Short description of company/working group

The Institute for Chemistry and Technology of Organic Materials (ICTOS) from the Technical University of Graz consists of about 50 scientists working on many different fields. The working groups cover many different research topics involving not only organic synthesis but also device fabrication as we are interested in potential applications and technology. Emphases thereby are placed on potentials of photochemistry, on the development of organic solar cells with high efficiencies and of the synthesis of Organic Field Effect Transistors (OFETs), Organic Light Emitting Devices or conductive inks via ROMP.

Institute for Technical Informatics, TU Graz

Address	Inffeldgasse 16; 8010 - Graz (Austria)
Phone / Fax	T:+43 316 873 6913
Size	250+
Organisation type	University

Contact Person

Name	Manfred Mücke
Position	PhD student
Phone / Fax	T:+43 316 873 6913
Email	muecke@iti.tugraz.at

Further Details

Short title	Searching applications for high-speed custom computing machines in bioinformatics.		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Both	Services: Both
	Licensing:	Lecture/Poster:	
	Manufacturing:		
	Sales and Marketing:		
Areas of activity:	Information processing & storage Other		

Project description

Custom tools to implement dedicated digital signal processing algorithms on programmable hardware (FPGAs).

Type of co-operation and qualification of co-operation partner

My research interest are hardware-accelerated computing solutions and respective design tools. Our interests might converge if you have either of the following needs:

High-Performance Computing - Need for extreme computing power exceeding current computing clusters capabilities.

Integration/Embedded Systems - Need for bringing excessive computing power to embedded platforms.

Generally - Interest in exploring hardware-accelerated computing solutions.

Short description of company/working group

I am a PhD student with TU Graz and CERN, Switzerland.

CERN is the European Laboratory for particle research located in Geneva, Switzerland. CERN builds experiments generating unprecedented amounts of data (TB/s). Digital Signal Processing implemented in programmable hardware (FPGAs) has become the dominant technology to tackle this task.

ITI is the Institute of Technical Informatics (TU Graz). Computer architecture, parallel programming and hardware description languages are the enabling basis to achieve efficient hardware implementation of increasingly complex algorithms.

Discussion has shown that many on-line computing challenges encountered in today's large-scale high-energy physics (HEP) experiments will soon become evident in bioinformatics, too.

I would like to improve my understanding of current Bioinformatics research problems to get a deeper understanding on possible transfer of gained experience (and tools) from HEP to Bioinformatics.

After having finished my PhD, I would be interested to enter the field of (hardware-accelerated) Bioinformatics as a researcher.

Institute of Physical Biology

Address	Veliko Mlacevo 59; 1290 - Grosuplje (Slovenia)
Phone / Fax	T:+386 41 504684
www	www.ifb.si
Size	1-10
Organisation type	Research Organisation

Contact Person

Name	Dr Alexis Zrimec
Position	CEO
Phone / Fax	T:+386 41 504684
Email	alexis@ifb.si
www	www.ifb.si

Further Details

Short title	Bioagents and Microbial Communities - Molecular Detection and Characterisation			
Type of co-operation (Offered, Requested)	Research Project: Offered	Networking: Requested	Services: Requested	Lecture/Poster: Requested
	Licensing: Requested			
	Manufacturing: Requested			
	Sales and Marketing: Requested			
Areas of activity:	Biotechnology Diagnostics Molecular Biology Cell Biology Instruments and equipment Biochemistry Imaging Nanotechnology, Services			

Project description

We are developing methods and standalone devices for rapid detection of pathogens and toxins in complex environments (air, water, soil, clothes...), where the potential bioagents are in extremely low, but infectious, amounts. Additionally, we are developing methods for analysing microbial communities in complex matrices using molecular biology tools for community profiling, detection of specific genes and their expression.

Our priorities are: 1) effective sampling, 2) rapid detection and quantification, and 3) integration into stand-off detectors.

The technologies used include real-time quantitative PCR, immunofluorescence, whole-cell and molecular biosensors, surface plasmon resonance, universal nucleic acid extraction methods, DNA profiling, biophotonics, nanotechnologies for miniaturisation and encapsulation, etc.

Type of co-operation and qualification of co-operation partner

Type of co-operation sought:

- Joint Research
- Commercial Agreement with Technical Assistance

Type of partner sought:

University, Research Laboratory, Industry

Task to be performed:

We are looking for partners for joint development of different methods, biomarkers and optoelectronic measurement devices, for market research and for commercialising the products.

Short description of company/working group

The Institute of Physical Biology is a private research organisation in the field of biological sensor systems development. We develop molecular and genomic tools for detection, characterization, quantification and risk assessment of biological agents (pathogens, toxicants, pollutants) in complex environmental samples. The know-how is then transferred to the development of micro- and optoelectronic measurement devices for laboratory or field use.

JOANNEUM RESEARCH Forschungsgesellschaft mbH, Laser Center Leoben

Address	Steyrergasse 17; 8010 - Graz (Austria)
Phone / Fax	T:+43 (0)3842 81260-2311 / F:+43 (0)3842 81260-2310
www	www.joanneum.at/lzl
Size	250+
Organisation type	Research Organisation

Contact Person

Name	Dr. Wolfgang Waldhauser
Position	Head of Thin Film Working Group
Phone / Fax	T:+43 (0)3842 81260-2311 / F:+43 (0)3842 81260-2310
Email	wolfgang.waldhauser@joanneum.at
www	www.joanneum.at/lzl

Further Details

Short title	We are developing functional thin coatings for biomedical applications (e.g. implants and prostheses, biosensors, biochips).		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Both	Services: Both
Areas of activity:	Licensing: Both	Lecture/Poster: L07	
	Manufacturing: Both		
	Sales and Marketing: Both		
	Nanotechnology		

Project description

<p>We employ low temperature coating techniques for the development of functional thin coatings for biomedical applications. Because of the low process temperature polymeric substrates can be coated, too. Target applications are biocompatible coatings for implants and prostheses (e.g. artificial heart), functional coatings for biosensors and biochips. Our technical equipment enables the development of such new coatings and the fabrication of prototypes as well as small series job-shop coating.</p> <p>Coating materials which can be deposited by employing these techniques are: titanium (Ti), gold (Au), chromium (Cr), aluminium (Al), diamond-like carbon (DLC), silicon (Si), titanium nitride (TiN), titanium oxide (TiO₂), chromium nitride (CrN), chromium oxide (CrO_x), silicon nitride (SiN_x), silicon oxide (SiO₂), etc.</p> <p>The coatings can be deposited onto metallic, ceramic and even polymeric substrates. Typical thickness of the coatings are in the range of a few nanometer up to a few micrometer.</p>

Type of co-operation and qualification of co-operation partner

<p>Type of co-operation sought:</p> <ul style="list-style-type: none"> - Joint project in R&D - Technology transfer <p>Type of partner sought:</p> <ul style="list-style-type: none"> - Industry - Research institutes, universities <p>Specific area of activity of the partner:</p> <ul style="list-style-type: none"> - Producer of medical devices - Research activities in the field of implants, biosensors, biochips etc. <p>Task to be performed:</p> <p>We are looking for partners for technology transfer.</p> <p>We are seeking cooperation partners who are demanding new functional thin coatings for their medical products. It would be beneficial if contacts to opinion leaders in hospitals would already exist.</p> <p>Furthermore the partners should have experience in testing the biomedical behaviour of new functional coatings. The partners should have a well-founded understanding on the requirements of functional coatings for medical applications.</p> <p>Target fields of applications are: implants and prostheses, biosensors, biochips</p> <p>We will support the partners with scientific knowledge in material science and thin film technology and we will deposit functional coating onto medical devices provided by the partners.</p>
--

Short description of company/working group

Our 14 research units make JOANNEUM RESEARCH one of the largest non-university research institutions in Austria. Our role as an innovative partner for business and administration is reflected in our wide range of services: apart from applied research and development for small and medium-sized enterprises we offer custom-designed technical business consulting and vast expertise in interdisciplinary management of complex research contracts at a national and international level.

The research JR is geared to the demands of business. The more than 400 employees of JR develop and improve products and processes in the fields of geological sciences and the environment, biotechnology and environmental technology, electronics and information processing, materials and processing as well as economy and technology. The range of services includes applied research and technological development, technology-oriented consulting and sophisticated technical services, consulting, support and project management in applications for national and international funding (e.g. EU framework programmes) with a special focus on small and medium-sized enterprises.

One of the 14 institutes of JR is the Laser Center Leoben in Niklasdorf, which has more than 17 years experience in applied research of laser materials treatment and surface coating. Initially starting from the Pulsed Laser Deposition (PLD) technique the Laser Applied Thin Film group at Laser Center Leoben is focussing its research and development on vacuum coating techniques working at low temperatures. The group is developing besides PLD processes also sputtering and ion-assisted techniques (e.g. with gridless ion sources) for temperature sensitive materials, so e.g. for polymer substrates. The coatings deposited by these techniques are applicable tools, machine elements, medical products (prosthesis, biosensors, biochips), etc.

JOANNEUM RESEARCH GmbH, Medical Technologies (MSG)

Address	Steyrergasse 17; 8010 - Graz (Austria)
Phone / Fax	T:0316/876-2140 / F:0316/876-2130
www	www.joanneum.at/msg
Size	250+
Organisation type	Research Organisation

Contact Person

Name	DI Manfred Bodenlenz
Position	Head of Focus Medical Technologies
Phone / Fax	T:0316/876-2140 / F:0316/876-2130
Email	manfred.bodenlenz@joanneum.at
www	www.joanneum.at/msg

Further Details

Short title	PROBES & SYSTEMS FOR IN VIVO DRUG TESTING: Novel approach for clinical studies of the pharmacokinetics, pharmacodynamics and the skin penetration of drugs			
Type of co-operation (Offered, Requested)	Research Project:	Both	Networking:	Requested
	Licensing:		Services:	Both
	Manufacturing:	Requested	Lecture/Poster:	L11
	Sales and Marketing:			
Areas of activity:	Clinical Studies, (Bio-)Medical Technology Pharmaceutical Research Instruments and equipment			

Project description

Profiling of intradermal pharmacokinetic and – dynamic parameters following topical administration of lipophilic drugs requires a novel sampling approach. We have developed minimally-invasive, membrane-free dermal sampling probes as well as wearable pump/collection devices in order to enable prolonged investigations based on continuous sampling of drugs and locally released cytokines. We present the methodology as well as results of clinical trials investigating the feasibility of lipophilic drug sampling.

Type of co-operation and qualification of co-operation partner

WE OFFER:

- 1) SCIENTIFIC COLLABORATION regarding PK/PD testing of drugs or method development, especially in cases where state-of-the-art methods do not apply.
- 2) DRUG TESTING in vitro/in vivo by applying unique Joanneum Research in vivo methodology and unique customized High-sensitive bioanalytical methods; in vivo usually in cooperation with the Medical University
- 3) MEDICAL DEVICE TESTING, in vitro/in vivo
- 4) IDEAS, EXPERIENCE with regard to in vivo metabolic monitoring & control in patients

WE SEARCH FOR:

- 1) DRILLING/PUNCHING/LASERING services for the perforation of small-diameter, biocompatible catheters or tubings (typical material PTFE OD 0.4-1.2mm, typical perforation/slit width 0.1-0.5mm)
- 2) RAPID-PROTOTYPING services to get mechanically stable housings/components, eg. for miniaturized portable pumps
- 3) PUMP & MICROFLUIDICS services/know-how

Short description of company/working group

EXPERTISE:

The Institute (MSG) has expertise in developing and providing specific sampling and sensing technologies, cutting-edge bioanalytics and the performance of in/ex vivo studies for drug PK-PD trials, medical device development and basic physiology research. MSG is used to actively contribute to international collaborative projects (ADICOL, CLINICIP, CARE-MAN, NANOBIOPHARMACEUTICALS). Our specific fields of expertise are

- § Body Interfaces & Sampling technology
- § Biosensors
- § Drug delivery
- § Clinical research

Body Interfaces & Sampling technology for PK-PD and continuous monitoring

Minimal invasive sampling techniques (Open-Flow Microperfusion, Microdialysis) are developed or custom-tailored enabling the investigation of substances (large, bound and lipophilic drugs, cytokines, peptides & proteins, metabolites, tracers, gas, ..) directly at the site of action (adipose tissue, muscle, dermis, brain, blood).

In combination with cutting-edge high sensitive laboratory bioanalytics (e.g. nanoHPLC-MS2 or FT-MS, in-house monolithic separation technologies, enhanced ELISAs, Luminex etc.) for low volume/concentration specimen or sensors for online measurements unique investigations are feasible.

Biosensors for continuous metabolite monitoring

Biosensor technology is developed, evaluated and integrated in monitoring and closed-loop systems to control metabolism in diabetes and intensive-care. Our novel optical O₂/Glucose-Fibre-Sensor (clinically tested, free of drift and interference) reached the stage for integration into monitoring systems.

Drug delivery for long term administration in chronic disorders

Based on the experience with sampling interfaces, MSG expand work to infusion technology for improved drug absorption kinetics to facilitate closed-loop approaches (eg. in glucose management).

Clinical Research in the fields of diabetes & metabolism, intensive care, closed-loop control, dermatology-cosmetics, pharmacology, oncology

Technologies are clinically evaluated and utilized for specific research services to the pharmaceutical industry and medical device producers in close cooperation with the Medical University Graz.

Joanneum Research, Health Management, Medical Informatics (MSG)

Address	Elisabethstraße 11a; 8010 - Graz (Austria)
Phone / Fax	T:+43 (0)316 876 2136 / F:+43(0)316 876 92136
www	www.joanneum.at/msg
Size	250+
Organisation type	Research Organisation

Contact Person

Name	MSc Peter Beck
Position	Group Leader
Phone / Fax	T:+43 (0)316 876 2136 / F:+43(0)316 876 92136
Email	peter.beck@joanneum.at
www	www.joanneum.at/msg

Further Details

Short title	Information systems for clinical and administrative processes and project evaluation in health care		
Type of co-operation (Offered, Requested)	Research Project: Requested	Networking: Both Offered	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	
	Sales and Marketing:		
Areas of activity:	Information processing & storage Services Other		

Project description

<p>We have developed a flexible platform for data management which is in use in clinical projects, quality management and research (www.healthgate.at). Currently applications exist in the fields of diabetes mellitus, hypertension, geriatrics and diabetes care.</p> <ul style="list-style-type: none"> - data collection from various sources - on-line data analysis - report generation - multi-user environment with role-based access control <p>Evaluation of health care projects is one of our fields of interest, recently it was demanded more strictly in the regional Reformpool projects in all Austrian provinces, where we are currently involved in several projects.</p>

Type of co-operation and qualification of co-operation partner

We offer our IT platform and technology support as well as our project evaluation experience to clinical / public health projects on the step to public roll-out.

Short description of company/working group

<p>Our research activity spectrum reaches from organizational and clinical health system concepts to software development for the healthcare system: The basis for providing optimum health services to as many people as possible is analysis, monitoring and improvement of the mechanisms underlying the complex, expensive health care systems. In close cooperation with local health authorities we work on the improvement of administrative and clinical processes in medical care, the optimisation of data management, patient-oriented care, and we perform cost analyses and project evaluations. We are currently involved in several real-life healthcare projects in Austria as well as in international research projects.</p> <p>We have strong experience and research interest in the following domains:</p> <ul style="list-style-type: none"> - chronic disease management - quality management in the care of chronically ill patients
--

- implementation of information systems in healthcare for administration and clinical care
- decision support and clinical decision making
- information retrieval
- workflow modelling
- patient education and patient empowerment
- cost analyses, cost-effectiveness, economic evaluation

Joanneum Research has provided the necessary know-how and manpower for setting up and running national competence centres as well as numerous large international projects including R&D activities on a European level, co-ordinating and participating in several IST projects in FP4, FP5 and FP6.

Ludwig Boltzmann Institute for Experimental and Clinical Traumatology

Address	Donaueschingenstraße 13; 1200 - Wien (Austria)
Phone / Fax	T:0316/380-4447
www	http://www.lbitrauma.org/
Size	11-50
Organisation type	Research Organisation

Contact Person

Name	PhD Gudrun Schmidt-Gann
Position	Post Doc
Phone / Fax	T:0316/380-4447
Email	gudrun.schmidt-gann@lbitrauma.org
www	http://www.lbitrauma.org/

Further Details

Short title	Preclinical Models			
Type of co-operation (Offered, Requested)	Research Project:	Requested	Networking:	Requested
	Licensing:		Services:	
	Manufacturing:		Lecture/Poster:	
	Sales and Marketing:			
Areas of activity:	Biotechnology Clinical Studies Molecular Biology			

Project description

Preclinical models in the field of ischemia/reperfusion, shock, inflammation, sepsis as well as hemostasis, wound/bone healing and tissue engineering with related analytical technology.

Type of co-operation and qualification of co-operation partner

Cooperation in the abovementioned fields to complement research competencies.

Short description of company/working group

The Research Institute for Traumatology of the Austrian Workers Compensation Board (AUVA) integrates the AUVA trauma center and the Ludwig Boltzmann Institute for Experimental und Clinical Traumatology (since 1980) (BoltzmannSociety) and is supported by the Trauma Care Consult.

The institute is located in the Lorenz Böhler Trauma Hospital in Vienna, Austria. In the year 2003 a stem cell laboratory was founded in Linz, Upper Austria and is run in conjunction with the bloodbank of the Red Cross.

Goals And Objectives

Scientific evaluation and improvement of diagnostic and therapeutic measures in emergency medicine and trauma surgery. Cooperation with various experts yields beneficial results in many fields of medicine. Special emphasis is put on training for health care professionals and implementation in clinical routine. The Research Center is involved in several Austrian and European research projects

Medical University of Graz - Artificial Vision Center

Address	Stiftingtalstraße 24; 8010 - Graz (Austria)
Phone / Fax	T:+43-316-385-72712
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Prof. Dr. Michaela Velikay-Parel
Position	group leader
Phone / Fax	T:+43-316-385-72712
Email	michaela.velikayparel@meduni-graz.at

Further Details

Short title	Artificial Vision Center		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking:	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	L09
	Sales and Marketing:		
Areas of activity:	Clinical Studies (Bio-)Medical Technology Instruments and equipment Trans- / Im- plantation		

Project description

An internationally unique research project

Our European research team has worked for many years on special implants, surgery methods, visual tests and a rehabilitation program for people who go blind due to congenital disorders of the retina (retinitis pigmentosa). There are around 3 million people worldwide suffering from retinitis pigmentosa and one third of them lose their eyesight and it is expected that the number is growing. Only in the past few years technology has reached the stage to deal with the complex system of vision in an effective way. Research in this field is pushing forward into new, untouched areas. Thereinafter it might be used also for other blinding retinal entities.

Recovering eyesight is a multi-phase process: First, a special implant (chip) is put into the eye of the blind patient, which builds the cornerstone for "artificial vision". The chip is the result of then years of arduous development work. Research has progressed so far, that the technological requirements for the first application on humans - the implantation are fulfilled. The following phases are part of a comprehensive rehabilitation program.

While the main goal of developing companies is to investigate the technological side of visual function - the clinical partners, scientist and physicians have to investigate all aspects of visual perception and thus create and establish the necessary patients support and assess and guide future development. However the electrical stimulation of the retina is a new informational input to the brain. The patients have to learn to deal with their newly gained visual perception

The main aim is to develop stimulation and learning strategies to enable the patients to fast learning about real life usage of their newly gained visual information and thus improve independency. Furthermore this learning process has to be studied in detail in order to draw conclusions for future developments.

Type of co-operation and qualification of co-operation partner

All types of organisation (Universities, research institutes, industry, SME's...)

Cooperation with neuropsychologists and –scientists, physicists, specialists on software development is necessary in order to develop various training programs under neuroscientific principles to enhance the learning process. This process should be followed in detail and conclusions drawn for future developments. The findings should be transformed into a scientifically based and practically proven rehabilitation program.

Scientific based observation methods to record behavioural changes on orientation, navigation and social contacts as well as the impact on quality of life are the principal tasks.

Short description of company/working group

Together with European partners our research team has worked for many years on special implants, surgery methods, sight tests and a comprehensive rehabilitation program for people who go blind due to congenital disorders of the retina (retinitis pigmentosa). There are around 3 million people worldwide suffering from retinitis pigmentosa, and one third of them lose their eyesight. The goal of our team is to develop an innovative treatment to enable these blind people to see light and shadow as well as contours again. The project has generated substantial public interest in Austria and is supported by extensive media presence.

Medical University of Graz - Dep. of Int. Med.

Address	Auenbruggerplatz 15; 8036 - Graz (Austria)
Phone / Fax	T:++43-316-385-2911
Size	250+
Organisation type	University

Contact Person

Name	Univ. Prof. Dr. Ernst Pilger
Position	head of department
Phone / Fax	T:++43-316-385-2911
Email	ernst.pilger@meduni-graz.at

Further Details

Short title	Department of Internal Medicine		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking:	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	
	Sales and Marketing:		
Areas of activity:	Clinical Studies Diagnostics Molecular Biology Cell Biology		

Short description of company/working group

- a) Division of Angiology
- b) Division of Endocrinology and Nuclear Medicine
- c) Division of Gastroenterology and Hepatology
- d) Division of Haematology
- e) Division of Cardiology
- f) Division of Nephrology and Haemodialysis
- g) Division of Oncology
- h) Division of Rheumatology
- i) Division of Pulmonology

Medical University of Graz - Dep. of Int. Med. - Cardiology

Address	Auenbruggerplatz 15; 8036 - Graz (Austria)
Phone / Fax	T:+43 316-385 -2544
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Prof. Dr. Helmut Brussee
Position	group leader
Phone / Fax	T:+43 316-385 -2544
Email	helmut.brussee@meduni-graz.at

Further Details

Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:
Areas of activity:	Clinical Studies (Bio-)Medical Technology Diagnostics	

Medical University of Graz - Dep. of Int. Med. - Diabetes Group

Address	Stiftingtalstraße 24; 8010 - Graz (Austria)
Phone / Fax	T:+43-316-385-72837
Size	250+
Organisation type	University

Contact Person

Name	Dr. Werner Regittnig
Position	senior scientist
Phone / Fax	T:+43-316-385-72837
Email	Werner.Regittnig@healthgate.at

Further Details

Short title	Novel Glucose-Controlled Insulin Delivery System for the Treatment of Type 1 Diabetes		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Offered Offered Requested Requested	Networking: Services: Lecture/Poster: P23
Areas of activity:	Clinical Studies (Bio-)Medical Technology Instruments and equipment		

Project description

Special indwelling catheters, like microdialysis (MD) probes, microperfusion (MP) probes or porous tissue contactors (PTC), are capable of delivering fluids to, and sampling fluids from, a body tissue (e.g., subcutaneous adipose tissue). The basic idea underlying this novel system for the treatment of diabetes is to use such a catheter both to deliver insulin to the subcutaneous tissue and to simultaneously sample subcutaneous interstitial fluid (ISF) for the frequent or continuous measurement of glucose.

The catheter for insulin delivery and simultaneous ISF sampling is inserted into the subcutaneous adipose tissue of the patient and then connected to an externally worn, pager-sized control unit using two thin, flexible tubes. The control unit comprises two miniature pumps, a sensor unit, a controller, a battery, and a perfusate reservoir filled with perfusate fluid containing insulin at a high concentration (e.g., 100 U/ml).

Pump 1 transports the perfusate fluid from the reservoir via the inlet tubing into the catheter, and pump 2 sucks the ISF from the catheter through the outlet tubing to the sensor flow chamber, which contains a glucose sensor and a conductivity sensor (for determining the catheter exchange efficiency). The glucose measurements are done with either an intermittent glucose sensor using dry chemistry technology (e.g.: multiple test strip drum) or continuous glucose sensor.

The controller acquires data from the sensors and converts them into blood glucose readings. Based on the blood glucose readings, the controller calculates the appropriate insulin delivery rate.

Subsequently, the insulin delivery rate is adjusted by altering the flow rate of pump 1 (e.g., between 0.5 and 5.0 microL/min). Depending on the sensor system used, the flow rate of pump 2 may be fixed to a value lower than that of pump 1 (e.g., 0.5 microL/min). Also, pump 2 may operate discontinuously.

Innovative aspects advantages:

A glucose-controlled insulin delivery system ('artificial pancreas') utilizing such a catheter for insulin delivery and simultaneous ISF sampling may offer important advantages over those systems previously described:

First, this novel system possesses just one instead of two catheters, which would allow sensing, delivery and control components to be combined into one design to yield a fully integrated pager-sized device.

Second, preliminary experiments performed to explore the effect of insulin on the glucose concentration in the ISF of subcutaneous adipose tissue suggest that the high insulin concentrations present during insulin delivery in the tissue surrounding the catheters may lead to the development of a stable relationship between the blood glucose concentration and the glucose concentration in the ISF sampled by the catheters, thereby allowing an improved estimation of plasma glucose levels from measured local interstitial glucose concentrations.

Third, because a relatively large volume of ISF is exchanging solutes with the perfusion fluid of the catheter, the rate of insulin absorption from ISF into the bloodstream may be higher when insulin is delivered by such catheters as compared to subcutaneous insulin administration by conventional needles. This may be beneficial for the design of a control algorithm.

Market applications:

The potential market of this novel glucose-controlled insulin delivery device seems to be comparable to the market of insulin pumps. Insulin pumps are increasingly used by type 1 diabetic patients. Type 1 diabetes is currently affecting about 0.5% of the population in developed countries and, like type 2 diabetes, is increasing in incidence (3% per year). People with type 1 diabetes have to administer insulin from external sources for survival. Administration of exogenous insulin by means of the subcutaneous route provides the basis of the current insulin therapy. In the majority of the insulin-requiring diabetic patients, insulin is administered in the form of a bolus subcutaneous injection. However, an increasing number of patients is using external pumps to administer insulin in the form of a continuous subcutaneous infusion (insulin pump therapy). In the year 2000, there were more than 200 000 diabetic subjects worldwide treated with insulin pumps. In the USA, Germany and France there were about 100 000, 20000, and 4000 pump users, respectively. In the USA and Germany, the yearly increase rate in pump sales is approaching 40% and, in France, this rate is 17%. The cost for the insulin pump and the supplies needed to begin therapy averages about \$5000. The infusion set and catheters must be purchased regularly at a yearly cost of approx. \$1500. The annual worldwide insulin pump and infusion set market is approximately 1 billion dollar.

Type of co-operation and qualification of co-operation partner

Type of partner sought: Industrial Partner

The specific area of activity of the partner:

The industrial partner may be a manufacturer of medical devices used in the management of diabetes (e.g.: insulin pump manufacturer, glucose meter manufacturer)

The tasks to be performed of the partner sought:

The industrial partner should provide support in the manufacturing, marketing, advertising and distribution of the system

Short description of company/working group

University group starting a spin-off company.

Medical University of Graz - Dep. of Int. Med. - EBM Review Center

Address	Auenbruggerplatz 14; 8036 - Graz (Austria)
Phone / Fax	T:+43-316-385-7708
Size	250+
Organisation type	University

Contact Person

Name	OA Dr. Karl Horvath
Position	group leader
Phone / Fax	T:+43-316-385-7708
Email	karl.horvath@klinikum-graz.at

Further Details

Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:
Areas of activity:	Information processing & storage Clinical Studies Other	

Medical University of Graz - Department of Obstetrics and Gynaecology

Address	Auenbruggerplatz; 8036 - Graz (Austria)
Phone / Fax	T:2201 / F:3061
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Prof. Dr. Andrea Frudinger
Position	Professor
Phone / Fax	T:2201 / F:3061
Email	andrea.frudinger@meduni-graz.at

Further Details

Short title	autologous myoblasts for incontinence		
Type of co-operation (Offered, Requested)	Research Project: Both Licensing: Manufacturing: Requested Sales and Marketing:	Networking: Both Services: Lecture/Poster:	
Areas of activity:	Biotechnology Clinical Studies		

Medical University of Graz - Department of Obstetrics and Gynaecology

Address	Auenbruggerplatz 14; 8036 - Graz (Austria)
Phone / Fax	T:2150 / F:3061
Size	250+
Organisation type	University

Contact Person

Name	MD Martina Ballon
Position	Oberärztin
Phone / Fax	T:2150 / F:3061
Email	m.ballon@gmx.net

Further Details

Short title	myoblast implantation for incontinence		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Both	
	Licensing:	Services:	
	Manufacturing: Both	Lecture/Poster:	
	Sales and Marketing:		
Areas of activity:	Biotechnology Clinical Studies (Bio-)Medical Technology Cell Biology Trans- / Im- plantation		

Medical University of Graz - Dept. of Int. Med. - EBM Review Center

Address	Auenbruggerplatz 14; 8036 - Graz (Austria)
Phone / Fax	T:+43-316-385-7708
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Doz. Dr. Andrea Siebenhofer
Position	group leader
Phone / Fax	T:+43-316-385-7708
Email	andrea.siebenhofer@meduni-graz.at

Further Details

Short title	Creation of systematic reviews on a number of different medical topics using a validated evidence based medicine tool.		
Type of co-operation (Offered, Requested)	Research Project: Offered	Networking: Offered	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	
	Sales and Marketing:		
Areas of activity:	Information processing & storage Clinical Studies Other		

Project description

Evidence-based medicine (EBM) is the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients. The practice of evidence-based medicine means integrating individual clinical expertise with the best available external clinical evidence from systematic research.

The key elements describing the "evidence-based medicine paradigm" are: Wherever possible, doctors use information from systematic, reproducible and unbiased (that is, without systematic error) studies (external evidence), in order to increase their confidence in the usefulness of a diagnostic test, the prognosis as well as the effectiveness of a therapy. The understanding of elementary rules of evidence is necessary to understand the medical literature and adequately apply the results found therein.

However, given the overwhelming quantity of biomedical literature available, applying the principles of evidence-based medicine to daily clinical practice is a task which cannot be performed by the average doctor providing patient care. He has neither the time, the resources, nor the know-how to carry out a search, evaluate the studies found and pool the data presented in them.

Our main activities are the creation of systematic reviews on a number of different medical topics, with a focus on issues related to chronic diseases.

One of our projects is comprised of four systematic reviews on aspects of diabetes mellitus: short acting insulin analogues in patients with type 1 diabetes mellitus, short acting insulin analogues in patients with type 2 diabetes mellitus, long acting insulin analogues in patients with type 1 diabetes mellitus and long acting insulin analogues in patients with type 2 diabetes mellitus. In addition to diabetes, further systematic reviews are on topics related to hypertension. This choice of topics reflects the specialties of our university staff in their current clinical practice.

The results of our systematic reviews will then serve for health care providers, insurance companies and national health institutes as the basis for:

- the description and evaluation of the present standard of knowledge concerning diagnostic and therapeutic procedures of selected diseases,
- generation of scientific elaborations, expert opinion and comments on questions of quality and economic efficiency of benefits adducted by compulsory health insurances,
- evaluation of evidence based guidelines for the epidemiologically most important diseases,
- release of recommendations concerning Disease Management Programs (DMP)
- evaluation of the benefit of pharmaceuticals
- provision of general information concerning quality and efficiency of health care for all citizens.

LITERATURE

Sackett DL, Richardson WS, Rosenberg W, Haynes RB (1998) Evidence-based Medicine. How to practice and teach EBM. Churchill Livingstone, Edinburgh, London

Greenhalgh T (2000) Einführung in die Evidence-based Medicine. Kritische Beurteilung klinischer Studien als Basis einer rationalen Medizin. Verlag Hans Huber, Bern

Application Domains: Information processing, information systems, Medicine, health

Type of co-operation and qualification of co-operation partner

Type of partner sought: industry, research organisation, health care providers, national institutes of health, insurance companies

Short description of company/working group

Steadily growing group of currently 4 medical scientists.

Medical University of Graz - Institute of Hygiene

Address	Universitätsplatz 4; 8010 - Graz (Austria)
Phone / Fax	T:+43(316)3804363
www	www.meduni-graz.at/hygiene/moldiag.html
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Prof. Dr. Harald Kessler
Position	group leader
Phone / Fax	T:+43(316)3804363
Email	harald.kessler@meduni-graz.at
www	www.meduni-graz.at/hygiene/moldiag.html

Further Details

Short title	Molecular Diagnostics		
Type of co-operation (Offered, Requested)	Research Project: Offered	Networking: Services: Offered	Lecture/Poster:
Areas of activity:	Diagnostics Molecular Biology		

Project description

Our expertise includes:
-Standardized and largely automated molecular detection of pathogens
-Real-time PCR
-RT-PCR (pathogens, cytokines)
-Sequencing

Medical University of Graz - Institute of Pathology

Address	Auenbruggerplatz 25; 8036 - Graz (Austria)
Phone / Fax	T:+43 316-380-4404
www	www.bioresource-med.at
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Prof. Dr. Kurt Zatloukal
Position	group leader
Phone / Fax	T:+43 316-380-4404
Email	kurt.zatloukal@meduni-graz.at
www	www.bioresource-med.at

Further Details

Short title	IT Solutions for Personalized Medicine, Imaging and Biobanking		
Type of co-operation (Offered, Requested)	Research Project: Offered	Networking:	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	P16
	Sales and Marketing:		
Areas of activity:	Biotechnology Information processing & storage Diagnostics Pharmaceutical Research Molecular Biology Cell Biology		

Project description

An increasingly important aspect for medicine in the 21st century is the growing need for treatment of many diseases on the level of the individual patient and for improving the efficacy of the drug development process. Such approaches are made possible by emerging resources, such as biobanks, large repositories of biological samples linked to medical data, and information extracted from these samples, e.g. gene expression profiles, proteomic and metabolomic information. Such resources require completely new approaches with respect to the IT infrastructure which must provide sample tracking and management, access control and guaranteeing patients' anonymity, data management and information mining. Owing to the complexity of the data associated with such samples, an important aspect of such an infrastructure is to provide tools which are specifically designed to analyze and visualize extremely large, complex datasets.

Our efforts to implement one of the worlds largest biobanks at the Medical University of Graz, at the Institute of Pathology have prompted the implementation of such an IT infrastructure. Besides the issues of sample management and tracking, anonymization, prevention of patient re-identification through the concept of k-anonymization, one important aspect which is currently addressed is visual data mining, which is addressed in the GenView and VIPER projects [www.geneview.org]. Complex and heterogeneously structured data (laboratory parameters, diagnosis, treatment and outcome, micro-array analysis data, and even images) are linked to the biobank samples and data mining within these data sets is supported by exploiting human visual capacities. Complex data are coded in glyphs to allow immediate perception of similarities or differences and which can be interactively arranged and grouped in various ways. Interactive selection and browsing of metabolic pathways and signaling pathways provide additional information revealing the biological functions. Through a close link between several input channels, which are simultaneously active, and by immediate visualization of the steps of the analysis, the expert is provided with a tool for the interactive exploration of complex data spaces. As input parameter for analysis and data mining algorithms this system employs the human capacity to grasp complex patterns and correlations and thus allows to reveal hidden structures.

Type of co-operation and qualification of co-operation partner

The partner should be interested in jointly developing visual data mining solutions providing technical expertise and experience in the processing, analysis and visualization of large datasets of highly complex structure to be used for research in personalized medicine.

Short description of company/working group

The group is implementing one of the largest tissue biobanks world-wide, as a resource for biomedical research and drug development. The work is funded by grants from national and European sources.

Medical University of Graz - Res. Infrastr. & Res. Man. - Biobank

Address	Stiftingtalstraße 24; 8010 - Graz (Austria)
Phone / Fax	T:++43-316-385-72718
Size	250+
Organisation type	University

Contact Person

Name	Dr. Karine Sargsyan
Position	head of division
Phone / Fax	T:++43-316-385-72718
Email	Karine.Sargsyan@meduni-graz.at

Further Details

Short title	NUBI - Nutrition and Bioefficacy		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Services:	
	Licensing: Requested	Lecture/Poster: L02	
	Manufacturing: Requested		
	Sales and Marketing: Requested		
Areas of activity:	Biotechnology Information processing & storage Diagnostics Pharmaceutical Research Molecular Biology Cell Biology Drug Targeting Biochemistry Imaging Nanotechnology		

Project description

Nutrition and bioefficacy (NUBI) is a project which intends to design, develop and validate obesity therapeutic and preventive agents via establishment of correlation of specific nutritional compounds and gene expression (signalling) including disease specific genes and biomarkers, under the vision of diagnostic technologies. Nutrigenomic research is the overall synthesis of three research fields: genomics, nutritional sciences and white biotechnology and is concerned primarily with nutrition-related diseases such as obesity. Via combination of our knowledge in all these fields we will work out therapeutic and preventive agents for obesity based on nutritional signalling.

Epidemiological studies repeatedly show associations between food intake and the incidence and severity of chronic diseases such as obesity. The idea, however, that foods contain bioactive molecules that can affect physiology and gene expression is a relatively new one. Dietary molecules are now known to affect gene expression directly or indirectly after modification by primary or secondary metabolism. Some components of foods can act (1) as ligands for transcription factors, (2) as positive or negative activators of signal transduction pathways or (3) as ligands for nuclear receptors. Genistein, vitamin A, and hyperforin are just a few well documented examples of dietary substances that can bind directly to nuclear receptors and influence gene expression.

The scientific objective of this cooperative research is to characterize the role of newly identified metabolic regulators within the nuclear receptor superfamily, including the PPARs, LXRs, FXR, CAR and PXR, as targets of nutrients and other natural products that have direct signalling and regulatory effects on metabolic pathways and to determine the cis- and trans-Paneth cell regulatory genes. Natural Products and Nuclear Receptors: PPARs - Important metabolic regulatory functions have recently been identified for several new members of the nuclear hormone receptor superfamily, including the PPARs, LXRs, FXR, CAR and PXR. All of these receptors are relatively promiscuous, recognizing both endogenous and exogenous ligands that often share little or no structural similarity, therefore these receptors are potential mediators of nutrients and other natural products that have beneficial effects. Epidemiological studies suggest that the alternative digestive pathways have very different effects on development of degenerative diseases like obesity, diabetes and carcinoma. Natural Products and Nuclear Receptors: PPARs Identify nutritional products and other natural products that regulate the activity of specific nuclear hormone receptors, and define the active agents that modulate receptor functions and by characterizing the effects of such novel receptor ligands at the levels of receptor function and regulation of expression of target genes in appropriate tissue. Still nutrigenomics is a science, which can be customized through personalized nutrition.

So, project NUBI is planning to establish high level expertise in field of nutrigenomics, to research new insights of the correlation of specific nutritional compounds and gene expression, as well as epigenetic inheritance of nutritional effects, to affect above mentioned development of degenerative diseases like obesity via personalized nutrition on behalf of human being.

Type of co-operation and qualification of co-operation partner

We are looking for competent innovative companies (SMEs or industry) or research units, especially in the field of nutrition or diagnostics that would like to strike a new path. On one hand, the co-operation partners are expected to participate in the research project and producing new aspects linked to the field of nutrigenomics in order to complement the knowledge of our group, concerning e.g. analytical methods. On the other hand, as we expect to develop marketable products, we are looking for future partners for the production and marketing of those substances or nutraceuticals. Our co-operation partners can be local players as e.g. dairies, bakeries, etc. as well as multinational enterprises.

Short description of company/working group

The new Division Biobank at the Medical University of Graz is a very complex structure combining several kinds of medical samples and the relevant clinical data.

Medical University of Graz - Res. Infrastr. & Res. Man. - Biobank

Address	Stiftingtalstraße 24; 8010 - Graz (Austria)
Phone / Fax	T:++43-316-385-73019
Size	250+
Organisation type	University

Contact Person

Name	Dr. Michaela Bayer
Position	QM Biobank
Phone / Fax	T:++43-316-385-73019
Email	Michaela.Bayer@klinikum-graz.at

Further Details

Short title	Biobanking, Quality management, Sample management		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Both
Areas of activity:	Information processing & storage Molecular Biology Cell Biology Services		

Project description

Biobanking, Quality management, Sample management

Type of co-operation and qualification of co-operation partner

Biobanking, Quality management, Sample management

Short description of company/working group

Biobanking, Quality management, Sample management

Medical University of Graz - RU of Biomed. Eng. in Anesth. & Int. Care

Address	Auenbruggerplatz 29; 8036 - Graz (Austria)
Phone / Fax	T:+43 316 385-3907 / F:+43 316 385-3908
www	http://www.litscher.info/
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Prof. DI DDr. Gerhard Litscher
Position	Head of Research Unit
Phone / Fax	T:+43 316 385-3907 / F:+43 316 385-3908
Email	gerhard.litscher@meduni-graz.at
www	http://www.litscher.info/

Further Details

Short title	High-Tech Acupuncture®		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Services: Lecture/Poster:	
Areas of activity:	Clinical Studies (Bio-)Medical Technology Instruments and equipment		

Project description

Recent scientific studies show that the solution for numerous secrets of acupuncture lies in the brain. Back in the year 1997, the Research Unit of Biomedical Engineering in Anesthesia and Intensive Care Medicine at the Medical University of Graz was able to scientifically prove that acupuncture needles can increase blood flow velocity in the brain specifically.

Selective proof of the specific effects of particular acupoints regarding changes in blood flow velocity can only be determined with new constructions developed in Graz. Double-blind cross-over studies were performed to master the placebo problem during acupuncture. Therefore laserneedles were applied at the skin but not inserted into the skin. It could be shown that non-invasive painless laserneedle stimulation can induce reproducible peripheral and specific cerebral changes. Thus far, about 150 scientific publications and 5 books have been published regarding the topic High-Tech Acupuncture by our research group.

Acupuncture has been used for medical treatment for thousands of years. A large number of empirical data is available, but the technical objectivation of effects was not possible up to now. Using needle, laserneedle and electro-stimulation and modern biomedical technics, changes in cerebral activity can be objectified but only give limited evidence in regard to the therapeutic effects of acupuncture.

Type of co-operation and qualification of co-operation partner

We are looking for partners who possess biomedical equipment and/or biosignal analysis for collaborative studies concerning the investigation of effects of acupuncture in humans. All stimulation methods (needle acupuncture, painless laserneedle acupuncture, electroacupuncture) and expertise in performing acupuncture studies are available.

Short description of company/working group

Biomedical Engineering in Anesthesia and Intensive Care Medicine at the Medical University of Graz is a research unit specialized in the field of neuromonitoring and high-tech acupuncture.

A large number of successful national and international research projects has been performed since its establishment in the year 1992 as a research group and in the year 2005 as a research unit at the Medical University of Graz.

The various projects cover neuromonitoring in anesthesia and intensive care, multivariable electrophysiologic monitoring in comatose patients, monitoring of the depth of anesthesia, and multiparametric monitoring of biosignals under various conditions.

Medical University of Graz - Stem Cell Research

Address	Universitätsplatz 3; 8010 - Graz (Austria)
Phone / Fax	T:+43.316.385.3067
www	http://www.meduni-graz.at/zmf/projekte/51.htm
Size	250+
Organisation type	University

Contact Person

Name	Dr. Katharina Schallmoser
Position	Researcher
Phone / Fax	T:+43.316.385.3067
Email	Katharina.Schallmoser@meduni-graz.at
www	http://www.meduni-graz.at/zmf/projekte/51.htm

Further Details

Short title	ANIMAL SERUM FREE PROPAGATION OF HUMAN MULTIPOTENT MESENCHYMAL STROMAL CELLS FOR CLINICAL APPLICATION			
Type of co-operation (Offered, Requested)	Research Project:	Offered	Networking:	Both
	Licensing:	Offered	Services:	
	Manufacturing:	Offered	Lecture/Poster:	L13
	Sales and Marketing:			
Areas of activity:	Biotechnology Clinical Studies (Bio-)Medical Technology Diagnostics Molecular Biology Cell Biology Imaging Trans- / Im- plantation			

Project description

<p>Objective: Medical progress in the field of Mesenchymal Stromal Cell (MSC) therapy has so far mainly been hampered by the lack of technology to produce adult MSC in appropriate quantity. Current State of the Art is to expand MSC under the aegis of fetal bovine serum (FBS) harboring the risk for xenoimmunization and to transmit known (e.g., transmittable bovine spongiform encephalopathy, TSE or BSE) and unknown diseases. Avoidance of FBS would be a so far unmet breakthrough towards safer and more broadly applicable SC investigational medicinal products (SC-IMP). In our previously developed two-step procedure we have shown to be able to propagate more than 1×10^8 MSC from small bone marrow aspirates within less than 4 weeks by replacing FBS by human platelet lysates (HPL). However, HPL still harbors the risk of disease transmission by human plasma and of anaphylactoid reactions in addition to incompatibilities due to blood group-related antibodies.</p> <p>Methods: We have invented a new standardized procedure to generate a unique human platelet lysate (HPL) from (1) otherwise discarded buffy coats by (2) pooling multiple units of human buffy coat-derived PRP to reduce lot variation, (3) removing the plasma to exclude the risk of transmitting isoagglutinins, plasma factors and in particular plasma-related diseases and allergic reactions and (4) substituting the removed plasma by a virtually antigen- and antibody-free additive solution (EU patent Application: EP06120857.5).</p> <p>Results: Under our previously published low density seeding protocol, using plasma-depleted platelet lysates with several additive solutions (n=3) we were able to propagate in the mean 6.7, 8.2 and 8.4 million compared to 9.2 million MSC in HPL supplemented culture starting from 1.4×10^4 MSC after 13 days, according to 8.5, 8.7 and 9.0 population doublings (PD) compared to 9.3 PD in HPL driven culture. Also cloning efficiency assays revealed comparable frequencies of fibroblast colony-forming units (CFU-F).</p> <p>Conclusions: The use of plasma-depleted human platelet lysates offers the possibility of large scale MSC propagation by avoiding the risks of human plasma and has to be investigated under good manufacturing practice conditions for further commitment to clinical application.</p>

Type of co-operation and qualification of co-operation partner

Pharmaceutical industry:

Assistance in improvement of HPL preparation and analysis of potent growth factors in human platelet lysates responsible for the stimulating effect on cell proliferation leading to the development of single factors as substitutes for HPL.

Short description of company/working group

The Stem Cell Therapy Research Group at the Medical University of Graz

In 2004, the Medical University of Graz has initiated an interdisciplinary research consortium (StemCellCluster Graz) to meet the needs of internationally recognized and competitive research in the field of stem cell biology and therapy. Dirk Strunk is heading a group of scientists from the Departments of Hematology and Stem Cell Transplantation (Maga. Dr. C. Bartmann, MTA D. Thaler, Dr. A. Reinisch) and the Clinic for Blood Group Serology and Transfusion Medicine (Dr. E. Rohde, Dr. K. Schallmoser). Together with researchers from the Institute of Pathology and the Department of Transplantation Surgery these researchers have established a fruitful collaboration to study the biology, phenotype and function of adult stem cells from hematopoietic tissues. The network within the StemCellCluster Graz has recently been extended by a close collaboration with the core facility of molecular biology (Dr. Christian Gully) to study the genomics of adult human MSC derived from BM using a genome-wide array technology.

Latest technology and biological material resources necessary to realize the proposed goals are available. Notably, cell culture is performed and monitored according to good manufacturing practice (GMP) criteria.

Embedded in the infrastructure of the recently established Center of Medical Research of the MUG, which provides laboratories equipped for flow cytometry, confocal laser scanning microscopy, mass spectroscopy and gene array analysis, the latter being serviced by trained staff scientists, innovative stem cell applications could be established reflecting successful translation of basic research into applicable clinical technology.

Medical University of Graz - Stem Cell Research

Address	Universitätsplatz 3; 8010 - Graz (Austria)
Phone / Fax	T:+43.316.385.4087
www	http://www.meduni-graz.at/zmf/projekte/51.htm
Size	250+
Organisation type	University

Contact Person

Name	Dr. Dirk Strunk
Position	group leader
Phone / Fax	T:+43.316.385.4087
Email	dirk.strunk@meduni-graz.at
www	http://www.meduni-graz.at/zmf/projekte/51.htm

Further Details

Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:
Areas of activity:	Biotechnology Clinical Studies (Bio-)Medical Technology Diagnostics Molecular Biology Cell Biology Imaging Nanotechnology	

Medical University of Graz - Vice-Rector for Strategy and Innovation

Address	Auenbruggerplatz 15; 8036 - Graz (Austria)
Phone / Fax	T:+43-316 385-3115
www	http://www.meduni-graz.at/rektorat/samonigg.html
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Prof. Dr. Hellmut Samonigg
Position	Vice-Rector for Strategy and Innovation
Phone / Fax	T:+43-316 385-3115
Email	rosemarie.gangl@meduni-graz.at
www	http://www.meduni-graz.at/rektorat/samonigg.html

Medical University of Graz, Center for medical research

Address	Stiftingtalstraße 24; 8010 - Graz (Austria)
Phone / Fax	T:+43 (0)316/385-73012 / F:+43 (0)316/385-73009
www	www.meduni-graz.at/zmf/biostatistics.html
Size	11-50
Organisation type	University

Contact Person

Name	Mag. Andrea Groselj-Strele
Position	statistician
Phone / Fax	T:+43 (0)316/385-73012 / F:+43 (0)316/385-73009
Email	andrea.strele@klinikum-graz.at
www	www.meduni-graz.at/zmf/biostatistics.html

Further Details

Short title	Biostatistics		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Both Both
Areas of activity:	Information processing & storage Clinical Studies Services		

Project description

The Division of Biostatistics offers expert advice and assistance in the following areas:

research planning (research design, randomization, sample selection, sample size); definition of the statistical analysis plan; data collection; data checking; data analysis; data presentation; data interpretation; publication of scientific results

These services are available to both ZMF and non-ZMF investigators. Priority is however given to ZMF investigators for whom the services are free of charge. The prices of biostatistical services for non-ZMF investigators are supplied on request. Education and training of scientific personnel in the use of biostatistic methods and statistical software complete the biostatistical services.

Type of co-operation and qualification of co-operation partner

All organizations (academia, industry, research institutes) involved in biomedical research.

Short description of company/working group

The Center for Medical Research (ZMF) is an affiliated research center of the Medical University of Graz, Austria. The ZMF provides infrastructure in terms of laboratory space and state-of-the-art instrumentation to academic research groups working at the ZMF. In addition, the ZMF currently harbors four core facilities which offer high-quality analytical services in the areas of molecular biology, microscopy, mass spectrometry and flow cytometry to ZMF researchers as well as to scientists from other academic institutions and from industry. A special feature of the ZMF is a shared Clinical Research Center enabling high quality clinical studies. In addition to the above, the Biostatistics Division provides expert assistance in experimental design and data analysis whilst an Audiovisual unit offers state of the art media solutions for optimal data communication.

Medical University of Graz, Center for medical research (ZMF I)

Address	Stiftingtalstrasse 24; 8010 - Graz (Austria)
Phone / Fax	T:(43) 0316 385 73013 / F:(43) 0316 385 73009
Size	11-50
Organisation type	University

Contact Person

Name	Dr. Heimo Strohmaier
Position	Group Leader
Phone / Fax	T:(43) 0316 385 73013 / F:(43) 0316 385 73009
Email	heimo.strohmaier@meduni-graz.at

Further Details

Short title	Use of Special Laboratory Infrastructure and of Flow Cytometry in Modern Biomedical Research		
Type of co-operation (Offered, Requested)	Research Project: Requested	Networking: Services: Offered	Lecture/Poster: PO1
Areas of activity:	Cell Biology Instruments and equipment Services		

Project description

The Department of Special Laboratory Units at the Center for Medical Research (ZMF) provides scientists with laboratory space and equipment as well as know-how to carry out their research in the following areas:

Studies employing genetically modified organisms in biosafety levels 2 and 3. This involves experiments (cloning, cell based assays, etc.) using primary cells isolated from human and murine tissues and/or established cell lines. In addition, work with infectious viruses and pathogenic microorganisms can also be conducted in high security labs.

In radioactive laboratories, researchers perform experiments using radioactive isotopes or radioactively labeled compounds, such as radioimmune assays, hybridization techniques, or in vivo labeling in cell culture. The animal facility at the ZMF allows researchers to keep small laboratory animals (mice, rats) under near-sterile conditions and offers adequate equipment to perform experiments in a standardized setting. In the histology unit, cryo-preserved and paraffine-embedded tissue specimen are prepared for subsequent analyses through various methods, such as immunohistochemistry, FISH or PCR.

The Flow Cytometry Core Facility at the ZMF offers state-of-the-art instrumentation for the performance of flow cytometry based studies. These include the analysis of cells as well as the purification of cells using either magnetic bead technology or high-speed digital cell sorting (FACS).

Type of co-operation and qualification of co-operation partner

All organizations (academia, industry, research institutes) involved in biomedical research. We want to offer our research services and we are seeking partners for the co-development of analytical methods, particularly in the field of flow cytometry.

Short description of company/working group

The Center for Medical Research (ZMF) is an affiliated research center of the Medical University of Graz, Austria. The ZMF provides infrastructure in terms of laboratory space and state-of-the-art instrumentation to academic research groups working at the ZMF. In addition, the ZMF currently harbors four core facilities which offer high-quality analytical services in the areas of molecular biology, microscopy, mass spectrometry and flow cytometry to ZMF researchers as well as to scientists from other academic institutions and from industry.

Medical University of Graz, Center for medical research (ZMF I)

Address	Stiftingtalstraße 24; 8010 - Graz (Austria)
Phone / Fax	T:0316-385-73504 / F:0316-385-73009
Size	250+
Organisation type	University

Contact Person

Name	Dr. Christian Guelly
Position	group leader
Phone / Fax	T:0316-385-73504 / F:0316-385-73009
Email	christian.guelly@klinikum-graz.at

Further Details

Short title	The core-facility molecular biology is a provider of molecular biology research techniques like full-genome microarrays and mutation analysis		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Offered P04
Areas of activity:	Biotechnology Molecular Biology		

Project description

The Molecular Biology Core Facility offers infrastructure and expert technical support for the successful application of key molecular biology techniques. Support is provided throughout the entire research process, i.e. from experimental design to final results.

We have implemented two microarray platforms for full-genome expression profiling and genome-wide DNA-analysis and complemented this technology with low(er)-throughput/high-accuracy real-time platforms. High quality nucleic acids prepared by semi-automated robotic systems are essential for various critical down-stream methods and guarantee reliable and reproducible data, especially when limited amounts of starting material or only formalin-fixed paraffin embedded tissues (FFPE) are available. Optimized Standard Operating Procedures (AQC, ISO9001:2000 certified) including the evaluation of intermediate results and parameters at critical experimental stages guarantee high quality data output.

Innovative aspects: Service Provider and cooperation partner in the field of molecular biology research. Know-how in various new technologies.

Type of co-operation and qualification of co-operation partner

Academic or non-academic scientists searching high quality technical assistance in the field of molecular biology as well as research institutions that want to outsource certain techniques like DNA sequencing, genotyping, expression profiling, etc.

Medical University of Graz, Center for medical research (ZMF I)

Address	Stiftingtalstraße 24; 8010 - Graz (Austria)
Phone / Fax	T:0316-385-73504 / F:0316-385-73009
Size	250+
Organisation type	University

Contact Person

Name	Dr. Birgit Ebner
Position	group leader
Phone / Fax	T:0316-385-73504 / F:0316-385-73009
Email	birgit.ebner@klinikum-graz.at

Further Details

Short title	novel technologies and services		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Offered P05
Areas of activity:	Biotechnology Molecular Biology		

Medical University of Graz, Center for medical research (ZMF I)

Address	Stiftingtalstrasse 24; 8010 - Graz (Austria)
Phone / Fax	T:0316 385 2989
Size	11-50
Organisation type	University

Contact Person

Name	M.Sc Alexander Hofmeister
Position	Head of preClinical Imaging
Phone / Fax	T:0316 385 2989
Email	a.hofmeister@meduni-graz.at

Further Details

Short title	preClinical Imaging, new service at the ZMF I		
Type of co-operation (Offered, Requested)	Research Project: Requested Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Offered P21
Areas of activity:	Imaging		

Project description

preClinical Imaging: in-vivo
1.) optical Imaging System (CRi Maestro): Maestro enables researchers to see smaller and deeper tumors sooner due to its extreme lowlight-level sensitivity. And it enables you to detect multiple labels within the same sample, by allowing for the separation of different signals, even if they overlap spectrally or spatially.
2.) micro Ultrasound System (VisualSonics): anatomical, functional and molecular imaging on one platform

3.) microCT System (Inveon Siemens): Designed to meet your throughput, resolution, and image quality needs, Inveon sets the standard for in vivo preclinical micro computed tomography. With a range of X-ray source and detector configurations available, the ability to adjust the scanner magnification between scans, and a suite of image reconstruction and data analysis tools, the Inveon delivers the most versatile preclinical CT solution in its class.

Type of co-operation and qualification of co-operation partner

Looking for research groups, which are interested in in-vivo Imaging

Short description of company/working group

The Center for Medical Research (ZMF I) was established in 2004 to provide a first class biomedical research infrastructure for both clinicians and basic research scientists working at the Medical University of Graz. Housed within an imposing, purpose built state of the art building located at the heart of the university hospital campus, the ZMF comprises of more than 4000 m² of well equipped laboratory and office space catering for cutting edge basic and applied biomedical and clinical research.

Medical University of Graz, Center for medical research (ZMF I)

Address	Stiftingtalstraße 24; 8036 - Graz (Austria)
Phone / Fax	T:++43-316-385-73001
www	http://www.meduni-graz.at/zmf/
Size	250+
Organisation type	University

Contact Person

Name	Univ.-Prof. Dr. Andreas Tiran
Position	Managing Director
Phone / Fax	T:++43-316-385-73001
Email	andreas.tiran@meduni-graz.at
www	http://www.meduni-graz.at/zmf/

Further Details

Short title	Center for medical research (ZMF I)		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Offered
Areas of activity:	Biotechnology Information processing & storage Clinical Studies (Bio-)Medical Technology Diagnostics Pharmaceutical Research Molecular Biology Cell Biology Drug Targeting Instruments and equipment Biochemistry Imaging Nanotechnology Services		

Project description

Organisation

Considerable effort has been invested in the development of a modular organisational structure to maximize the efficiency and effectiveness of research conducted at the ZMF. Well equipped Conventional Laboratories are available to host individual research groups. Four Core Facilities (Molecular biology, Mass Spectrometry, Microscopy and Biophysics and Flow Cytometry) comprising of the most up to date equipment and well trained permanent technical staff are available to all researchers.

Restricted Access Laboratories cater for experimentation requiring special safety measures. A General and Special Laboratories Staff coordinates access to this infrastructure. A special feature of the ZMF is a shared Clinical Research Center enabling high quality clinical studies. In addition to the above, the Biostatistics Division provides expert assistance in experimental design and data analysis whilst an Audiovisual unit offers state of the art media solutions for optimal data communication.

Research and Administrative staff

The ZMF has assembled a first class permanent staff comprising of experienced scientists, skilled technicians, and administrative personnel. If requested, we will provide assistance to investigators at any stage of the research process, including experimental design, method development, high-throughput sample work-up and data interpretation and presentation.

Type of co-operation and qualification of co-operation partner

Access to the Center

Modern biomedical research is a challenging and competitive activity. To ensure the efficient use of the ZMF infrastructure all project proposals are critically reviewed by an independent commission and access to ZMF resources allocated on a merit basis.

Networking

The importance of networking for the stimulation of research activity is well known. The ZMF strives to provide a vibrant and stimulating environment that fosters communication and cooperation across medical disciplines and across boundaries between university and industry, enabling synergies between like-minded investigators to be identified and further developed.

Short description of company/working group

The Center for Medical Research (ZMF) was established in 2004 to provide a first class biomedical research infrastructure for both clinicians and basic research scientists working at the Medical University of Graz. Housed within an imposing, purpose built state of the art building located at the heart of the university hospital campus, the ZMF comprises of more than 4000 m² of well equipped laboratory and office space catering for cutting edge basic and applied biomedical research and clinical research.

Medical University of Graz, Center for medical research (ZMF I)

Address	Stiftingtalstr. 24; 8010 - Graz (Austria)
Phone / Fax	T:+4331638572962 / F:+4331638573009
www	www.meduni-graz.at/zmf
Size	11-50
Organisation type	University

Contact Person

Name	Dr Ruth Birner-Gruenberger
Position	Director Core Facility MS/Proteomics
Phone / Fax	T:+4331638572962 / F:+4331638573009
Email	ruth.birner-gruenberger@meduni-graz.at
www	www.meduni-graz.at/zmf

Further Details

Short title	Our core facility provides know-how and infrastructure for proteomic analysis.		
Type of co-operation	Research Project: Both	Networking: Both	
(Offered, Requested)	Licensing: Both	Services: Offered	
	Manufacturing: Both	Lecture/Poster: P07	
Areas of activity:	Sales and Marketing: Both Biochemistry, Services		

Project description

The ability to analyse the cellular proteome provides key insights into how cells function at the molecular level. The technical challenges of proteomics are protein identification and quantification in complex biological samples, identification of post translational modifications and analysis of non covalent complexes.

Currently, standard bottom up proteomics with high resolution (peptide mapping and sequencing of protein digests by nanoHPLC-nanoESI-MS/MS) as well as top down protein analysis (fragmentation of whole proteins by nanoESI-MS/MS) is established.

Protein separation by liquid chromatographic (FPLC) and electrophoretic methods (one and two-dimensional gelelectrophoresis) as well as protein digestion (by trypsin) and desalting are also made available.

Instrumentation:

LTO-FT (Thermo):

Consisting of a linear ion trap and a FT-ICR-MS, this mass spectrometer is able to deliver MSⁿ spectra with mass accuracies of less than 1ppm on a regular basis. It is equipped with two analyzers and two separate detection systems, which allows for operating the LTO-FT as two separate mass spectrometers simultaneously. The instrument is equipped with a NanoESI source and can be coupled to an Agilent1200 NanoHPLC system. For fragmentation CID and ECD are available.

FPLC (BioLogic, BIO-RAD):

Consisting of a binary gradient low pressure LC system with UV detection and a fraction collector, the FPLC is the tool of choice to separate and clean up proteins.

Gelelectrophoresis (BIO-RAD, GE Healthcare):

Instrumentation for one- and two-dimensional gelelectrophoresis for different gel sizes is available.

Type of co-operation and qualification of co-operation partner

scientists interested in protein/proteomic analysis

Short description of company/working group

The ZMF is the center for medical research at the Medical University of Graz and offers state of the art infrastructure and highly trained personnel.

Medical University of Graz, Center for medical research (ZMF I)

Address	Stiftingtalstrasse 24; 8010 - Graz (Austria)
Phone / Fax	T:0316 385-73005
Size	250+
Organisation type	University

Contact Person

Name	Dr. Harald Köfeler
Position	Director
Phone / Fax	T:0316 385-73005
Email	harald.koefeler@klinikum-graz.at

Further Details

Short title	Core Facility for Mass Spectrometry & Proteomics		
Type of co-operation (Offered, Requested)	Research Project:	Requested	Networking:
	Licensing:		Services:
	Manufacturing:		Lecture/Poster:
	Sales and Marketing:		Offered P08

Areas of activity: Biochemistry
Services

Project description

Mass Spectrometry coupled to Chromatography can be used in a variety of different ways. Our equipment allows quantitation and identification of drugs, lipids and metabolites. Technologies to be established within the next 2 years will comprise identification of proteins (proteomics) and screening of lipids (Lipidomics).

Type of co-operation and qualification of co-operation partner

Ideally our co-operation partners should have well defined research projects and be in need for solutions to their analytical problems.

Short description of company/working group

The Core Facility for Mass Spectrometry provides solutions for analytical problems by use of up-to-date mass spectrometric equipment operated by skilled scientists and technicians. In recent years mass spectrometry has emerged as a powerful analytical tool in medical research. High sensitivity and even more so superior selectivity contributes substantially to this fact. Particularly the constantly improving ability to work on a broad variety of biopolymers like proteins makes mass spectrometry an indispensable analytical tool.

Medical University of Graz, Department of Internal Medicine

Address Auenbruggerplatz 15; A-8036 Graz (Austria)
Phone / Fax T:0043-316-385-2863 or -6159 (Lab) / F:0043-316-385-3062
www www.nuigalway.ie/msi/keynote2006.htm
Size 250+
Organisation type University

Contact Person

Name **Priv.-Doz. Dr.med. Dr.rer.nat. Zeno Földes-Papp**
Position Principal Investigator, Project Leader
Phone / Fax T:0043-316-385-2863 or -6159 (Lab) / F:0043-316-385-3062
Email Zeno.Foldes-Papp@meduni-graz.at
www www.nuigalway.ie/msi/keynote2006.htm

Further Details

Short title **Fluorescence fluctuation spectroscopic and imaging approaches to the study of single molecules in solution and within live cells**

Type of co-operation (Offered, Requested) Research Project: **Both** Networking: Requested
Licensing: Services:
Manufacturing: Lecture/Poster:
Sales and Marketing:

Areas of activity: Diagnostics
Molecular Biology
Cell Biology
Instruments and equipment
Biochemistry
Imaging
Nanotechnology

Project description

Reentries of a single molecule in the confocal, femtoliter-sized probe region (about ten to the power of 10^{-16} L and less) are significant because during measurement times they give rise to fluctuation phenomena such as molecule number fluctuations at the single-molecule level. These fluctuations are the fundamental physical process on which, e.g., fluorescence auto- and two-color cross-correlation spectroscopy is based. It is found that the reentries obey certain conditions. In particular, the time constant of the mean value and the variance of the reentry probabilities are found. Further, the fraction of non-meaningful reentries is found for these experimental situations as well as the number of meaningful reentries. Therewith, the concentration dependence of the meaningful time that one can study bimolecular reactions of the selfsame molecule in the confocal probe region is obtained. The meaningful time in the probe volume is proportional to the diffusion time of the selfsame molecule and related inversely to the size of the given confocal probe volume. For small molecules, i.e. small diffusion times at a given size of the confocal probe region, one needs lower concentrations of molecules of the same kind in the bulk phase, whereas large molecules can be studied at higher concentrations. The selfsame molecule scenario is compared with the molecular scenario that a second molecule enters the probe volume at random as function of the meaningful time.

REFERENCES

Földes-Papp Z (2007). Fluorescence fluctuation spectroscopic approaches to the study of a single molecule diffusing in solution and a live cell without systemic drift or convection: a theoretical study. *Curr. Pharm. Biotechnol.* 8(5), 261-273.

Földes-Papp Z (2007). True single-molecule molecule observations by fluorescence correlation spectroscopy and two-color fluorescence cross-correlation spectroscopy. *Exp. Mol. Pathol.* 82(2), 147-155.

Braet C, Stephan H, Dobbie IM, Togashi DM, Ryder AG, Földes-Papp Z, Lowndes N, Nasheuer HP (2007). Mobility and distribution of replication protein A in living cells using fluorescence correlation spectroscopy. *Exp. Mol. Pathol.* 82(2), 156-162.

Földes-Papp Z (2007). Exploring the biomedical applications of microscopy and spectroscopy. *Exp. Mol. Pathol.* 82(2), 103.

Földes-Papp Z (2006). What it means to measure a single molecule in a solution by fluorescence fluctuation spectroscopy. *Exp. Mol. Pathol.* 80 (3), 209-218.

Földes-Papp Z, Baumann G, Kinjo M, Tamura M (2005). Single-phase single-molecule fluorescence correlation spectroscopy (SPSM-FCS). Distinguished article entry. In: J Fuchs, M Podda (Eds.), *Encyclopedia of Medical Genomics & Proteomics*, Marcel Dekker, New York (USA).

Földes-Papp Z, Ed. (2007). Half Special Issue "Exploring the Biomedical Applications of Microscopy and Spectroscopy". *Exp. Mol. Pathol.* 82 (2), 103-189.

Földes-Papp Z (2008). Viral Chip Technology for Genomic Medicine. In: HF Willard, GS Ginsburg (Eds.), *Handbook of Genomic Medicine*. Academic Press, New York (USA), in press. http://www.ybp.com/acad/ads/0707_elsev_genomic.html

Type of co-operation and qualification of co-operation partner

Type of co-operation: experimental scientists and research organizations, industry, SME

Short description of company/working group

Principal Investigator and Project Leader: during the last 6 years from 09/2007 – 09/2001, I made a sum of impact factors of more than 100.00 (2005/2006 JCR, Science Edition, PA, USA).

Biographical sketch:

I am a Biochemist and Molecular Biologist with theoretical and clinical specializations. I full-studied Medicine and Chemistry and have professional certifications as Consultant in Biochemistry from the Federal State of Berlin, Germany, and as Consultant in Immunology from Vienna, Austria (Clinical Specialization in Immunology in the Medical Routine Care Unit of Clinical Immunology and Laboratory, Medical University of Graz, 2001-2006). I received the M.D. degree (Dr.med.) in Medical Biochemistry from the Humboldt University Berlin, Germany, the Ph.D. degree in Macromolecular Chemistry (Dr.rer.nat.) from the University of Ulm, Faculty of Natural Sciences (Graduiertenkolleg 'Biomolecular Medicine' of the DFG), Germany, and the habilitation degree (PD) in Medical Biochemistry from the Medical University of Graz, Austria, on "Assays of Single Molecules in Solution". The primary focus of some current research interests of mine and research expertise is the theoretical and experimental analysis of biomolecules exemplified by, for example, immune complexes and genomic DNA in solution, single immobilized horseradish peroxidase molecules, individual gene variabilites (e.g., of the human herpes viruses, viral chips), single

DNA molecule sequencing, and sequence variabilities of chemically synthesized oligonucleotides described by fractal measures. I am also very interested in the physiological role of reactive oxygen and nitrogen species, in particular under high-altitude conditions. I author and co-author more than 90 articles (research papers) in international peer-reviewed scientific journals and books, and I own three USA and European patents (present patent enforcement is worldwide) on sequencing and detection of single DNA molecules. I am Appointed Member of the European Commission Grants Review Panel 2007: Key scientific evaluator in Brussels for collaborative, large-scale focused research projects (networks of excellence).

Medical University of Graz, Research Management

Address	Auenbruggerplatz 2; 8036 - Graz (Austria)
Phone / Fax	T:+4331638572018 / F:+4331638572030
www	www.meduni-graz.at
Size	250+
Organisation type	University

Contact Person

Name	Dr. Heidi Schmitt
Position	Technology Transfer Office
Phone / Fax	T:+4331638572018 / F:+4331638572030
Email	heidi.schmitt@meduni-graz.at
www	www.meduni-graz.at

Further Details

Short title	Research Management - Technology Transfer			
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Offered Offered Requested Requested	Networking: Services: Lecture/Poster:	Requested Offered
Areas of activity:	Biotechnology Information processing & storage Clinical Studies (Bio-)Medical Technology Diagnostics Pharmaceutical Research Molecular Biology Cell Biology Drug Targeting Instruments and equipment Biochemistry Imaging Nanotechnology Trans- / Im- plantatio			

Project description

The Medical University of Graz has a pool of various technologies, ranging from clinical molecular biology and diagnostics to medical engineering. Our researchers act interdisciplinary and dispose of a long experience in the mentioned fields. The Technology Transfer Office as an interface between research and industry focuses on information, advice, training and coaching in the fields of technology transfer and industrial cooperation. Your wishes in the fields of research and development are our command. For your specific projects we will find you qualified and competent researchers in the areas of medicine, medical engineering and biotechnology who dispose of appropriate know-how and will answer your questions accordingly. It is our aim to establish a long-lasting cooperation between researchers and enterprises, so the industry has ready access to the inventions and technologies of our researchers.

Type of co-operation and qualification of co-operation partner

We are looking for different cooperation partners from biomedical industry for joint research projects in various fields of biomedicine and life sciences. Together with partners from industry we would like to perform further development of existing prototypes to products.

Short description of company/working group

Technology Transfer Office of the Medical University of Graz. Active in different fields of biomedical research.

Medical University of Graz, Research Management

Address	Auenbruggerplatz 2; 8036 - Graz (Austria)
Phone / Fax	T:+4331638572017
Size	250+
Organisation type	University

Contact Person

Name	Dr. Margit Lachmann
Position	technology transfer
Phone / Fax	T:+4331638572017
Email	margit.lachmann@meduni-graz.at

Further Details

Short title	Center for Transfer of Knowledge and Technology in Medicine (ZMF III) - Looking for Partners and Tenants		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Requested Offered
Areas of activity:	Services		

Project description

The Medical University of Graz will increase the amount of space for medical research by a total of 6000 m². The Center for Medical Research III (ZMF III) will be established by 2009/2010 in close vicinity of the University Hospital, the already existing Center for Medical Research I (ZMF I) and the not yet erected campus of the Medical University of Graz (ZMF II). The ZMF III is supposed to provide enough room and infrastructure for spin-offs of the Medical University of Graz and the settlement of national and international enterprises specialized in medicine, biomedicine and life sciences. This concept focuses on the perfect co-operation between scientific research at the Medical University and its economic realization together with specific enterprises.

Type of co-operation and qualification of co-operation partner

We would like to get in contact with companies in the field of medicine or life sciences that are willing to establish offices or labs on the campus of the Medical University of Graz and its university hospital in order to identify their demands concerning infrastructure and know-how.

Short description of company/working group

Technology Transfer Office of the Medical University of Graz.

Medical University of Graz, Research Management

Address	Auenbruggerplatz 2; 8036 - Graz (Austria)
Phone / Fax	T:++43-316-385-72071
Size	250+
Organisation type	University

Contact Person

Name	Irmelin Küthe
Position	Fundraising
Phone / Fax	T:++43-316-385-72071
Email	irmelin.kuethe@meduni-graz.at

Further Details

Short title	Fundraising and Corporate Social Responsibility		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Both Both
Areas of activity:	Services		

Project description

The service unit fundraising provides information and offers projects for partners who are interested in integrating Corporate Social Responsibility (CSR) in their strategy.

Type of co-operation and qualification of co-operation partner

Any kind of company interested in receiving information about the concept of Corporate Social Responsibility (CSR) and the possibilities of implementing CSR with the Medical University of Graz as a partner, or companies which have already implemented CSR and would like to exchange ideas and experiences and/or are looking for new partners.

Short description of company/working group

The service unit fundraising is part of the Research Management Office of the Medical University of Graz. It supports selected research teams in finding Corporate Social Responsibility partners for their special research project.

Medical University of Graz-Inst. of Physiology-Physiol.Chemistry Group

Address	Harrachgasse 21/V; 8010 - Graz (Austria)
Phone / Fax	T:380-4264 / F:380-9630
Size	250+
Organisation type	University

Contact Person

Name	Ing. Josef Kellner
Position	Technician
Phone / Fax	T:380-4264 / F:380-9630
Email	josef.kellner@meduni-graz.at

Further Details

Short title	Sample Treatment and Preparation Technologies			
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Requested Offered Requested Requested	Networking: Services: Lecture/Poster:	Both Requested
Areas of activity:	(Bio-)Medical Technology Diagnostics Pharmaceutical Research Instruments and equipment Biochemistry Services			

Project description

Discardable easy-to-use prototype devices for efficient treatment of samples with reagents down to procedure-optimized small amounts of sample material and reagents have been developed. Saving of time and waste, reducing of the required amount of sample material and reagents combined with highest possible recoveries, avoiding of undesired contamination, denaturing and/or loss of sample material, improve of working safety if hazardous substances are intended to be used, are some of the features to facilitate everyday's laboratory work. Limited amounts of sample material, the use of expensive reagents or a desired increase of the number of possibly different investigations often implies the need for efficient handling of small volumes during sample preparation and/or fractionation in low or high through-put procedures. Suitable for cells, viruses, nucleic acids, proteins or other components, different types of devices for series of methods and protocols for universal samples in cell biology, biochemistry and molecular biology could be suggested.

Type of co-operation and qualification of co-operation partner

Type of partner sought:
Industry

Type of co-operation sought:
License agreement, commercial agreement with technical assistance

The partner should be a producer and distributor of discardable laboratory devices (e.g. reaction vessels). Manufacturing prototypes and testing devices within scientific projects should lead to licensing and commercialising the products.

Short description of company/working group

The working group of Physiological Chemistry at the Institute of Physiology is concerned with electrophoretical methods, protein purification and platelet aggregation.

Further informations:
<http://www.meduni-graz.at/physiologie/arbb/pc.html>

MKS Electronic systems Ltd.

Address	Rozna dol. C.XVII/22b; 1000 - LJUBLJANA (Slovenia)
Phone / Fax	T:+386-1-256-22-43
www	www.mks.si
Size	1-10
Organisation type	Research Organisation

Contact Person

Name	Drago Rudel
Position	Director
Phone / Fax	T:+386-1-256-22-43
Email	drago.rudel@mks.si
www	www.mks.si

Further Details

Short title	Introducing telecare and telemedicine at home		
Type of co-operation (Offered, Requested)	Research Project: Requested	Networking: Requested	Services: Requested
	Licensing:	Lecture/Poster:	
	Manufacturing:		
	Sales and Marketing:		
Areas of activity:	(Bio-)Medical Technology Instruments and equipment		

Project description

We are seeking for partners in research projects and for pilot applications of telecare and telemedicine solutions at homes, particularly for elderly population and patients with cronic diseases.

Type of co-operation and qualification of co-operation partner

partner cooperation at projects. telemedicine equipment,

Short description of company/working group

SME working in telecare since 1990.
References: 2 working networks providing telecare service in Ljubljana (capital) and Celje.

NEUROTH AG - Neuroth Fachinstitut Graz

Address	Mariahilferstraße 3; 8020 - Graz (Austria)
Phone / Fax	T:+43/316/712011
www	www.neuroth.at
Size	250+
Organisation type	Company

Contact Person

Name	DI Michael Uhl
Position	product specialist
Phone / Fax	T:+43/316/712011
Email	michael.uhl@neuroth.at
www	www.neuroth.at

Further Details

Type of co-operation (Offered, Requested)	Research Project:	Networking:
	Licensing:	Services:
	Manufacturing:	Lecture/Poster:
	Sales and Marketing:	
Areas of activity:	(Bio-)Medical Technology Instruments and equipment	

Oridis Biomed Forschungs- und Entwicklungs GmbH

Address	Stiftingtalstrasse 3-5; 8010 - Graz (Austria)
Phone / Fax	T:++43 316 325 776-21
www	www.oridis-biomed.com
Size	11-50
Organisation type	Company

Contact Person

Name	Wolfgang Senne
Position	CFO
Phone / Fax	T:++43 316 325 776-21
Email	senne@oridis-biomed.com
www	www.oridis-biomed.com

Contact Person

Name	Dr. Georg Casari
Position	CIO
Phone / Fax	T:++43 316 325 776-0
Email	casari@oridis-biomed.com

Contact Person

Name	Dr. Peter Amersdorfer
Position	Head of Business Development and Technol
Phone / Fax	T:++43-316-325776 17
Email	amersdorfer@oridis-biomed.com
www	www.oridis-biomed.com

Further Details

Short title	Biomarkers – Novel discoveries and clinical validation		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking:	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	
	Sales and Marketing:		
Areas of activity:	Biotechnology, Pharmaceutical Research Molecular Biology, Cell Biology, Drug Targeting		

Project description

In close collaborations with Medical University in Graz, Oridis has become an expert in medical validation of molecular targets and diagnostic signatures. Oridis has established a world wide network of industrial partners and clients in the health care and pharmaceutical sector that collaborate in validation Projects and clinical studies. A specific case study will be presented and the requirements of this rapid emerging market for targeted treatment solution presented.

Type of co-operation and qualification of co-operation partner

Oridis is working with a constantly growing network of medical and clinical partners to provide solutions and answers to the medical questions raised by our clients.
In particular ORIDIS is looking for partners in the area of oncology and inflammation that can add aspects to clinical validation or can extend the network of collaborators in those areas.

- Clinical development collaborations for Biomarkers
- Biomarker candidates (focus cancer)
- Collaborations for ORIDIS Biomarker Projects

Short description of company/working group

ORIDIS Biomed is a biopharmaceutical company, developing therapeutics, diagnostics and biomarkers (targeted treatment solutions) for liver diseases. Therapeutic programs include primary liver cancer (hepatocellular carcinoma, HCC), and metabolic liver diseases, such as alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH), where incidence rates are rapidly increasing due to modern life-styles, while treatment options are limited, expensive, and often ineffective.

ORIDIS Biomed uses its proprietary TISSOMICS™ platform also in its own research and development programs. In addition, the Company commercializes the TISSOMICS™ research platform in collaborations with industrial partners. ORIDIS Biomed is a privately held company, based in Graz, Austria

About TISSOMICS™

TISSOMICS™ is a proprietary disease-driven research platform enabling the medical validation of drug discovery approaches and biomarkers. ORIDIS Biomed has a license from the Medical University of Graz, Austria for the commercial access to BioResource-Med biobank, one of the world's largest collections of diseased human tissues and associated medical data. TISSOMICS™ has been successfully applied in co-operations and partnerships with leading pharmaceutical and biotechnology companies to deliver medical validation to their drug discovery or biomarker programs using optimized genomic and proteomic approaches.

Wolfgang Senne started his business life at the medical devices business of Siemens. During his career he held several executive positions in Europe and the USA, focusing on the development of new products and worldwide marketing within the life science area. In 2001, he joined GeneScan Europe AG, a biotech company focusing on microbiological analytical systems, where he held the positions of CFO, and CEO. Wolfgang Senne joins ORIDIS Biomed after holding interim executive manager position in a life science start-up.

Oridis Biomed Forschungs- und Entwicklungs GmbH

Address	Stiftingtalstrasse 3-5; 8010 - Graz (Austria)
Phone / Fax	T:++43 316 325 776-21
www	www.oridis-biomed.com
Size	11-50
Organisation type	Company

Contact Person

Name	Dr. Peter Hecht
Position	CEO
Phone / Fax	T:++43 316 325 776-21
Email	hecht@oridis-biomed.com
www	www.oridis-biomed.com

Further Details

Short title	Setting standards for Biomarkers		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking:	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	L15
	Sales and Marketing:		
Areas of activity:	Biotechnology Pharmaceutical Research Molecular Biology Cell Biology Drug Targeting		

Project description

In close collaborations with Medical University in Graz, Oridis has become an expert in medical validation of molecular targets and diagnostic signatures. Oridis has established a world wide network of industrial partners and clients in the health care and pharmaceutical sector that collaborate in validation Projects and clinical studies. A specific case study will be presented and the requirements of this rapid emerging market for targeted treatment solution presented.

Type of co-operation and qualification of co-operation partner

Oridis is working with a constantly growing network of medical and clinical partners to provide solutions and answers to the medical questions raised by our clients.

In particular ORIDIS is looking for partners in the area of oncology and inflammation that can add aspects to clinical validation or can extend the network of collaborators in those areas.

- Clinical development collaborations for Biomarkers
- Biomarker candidates (focus cancer)
- Collaborations for ORIDIS Biomarker Projects

Short description of company/working group

ORIDIS Biomed is a biopharmaceutical company, developing therapeutics, diagnostics and biomarkers (targeted treatment solutions) for liver diseases. Therapeutic programs include primary liver cancer (hepatocellular carcinoma, HCC), and metabolic liver diseases, such as alcoholic steatohepatitis (ASH) and non-alcoholic steatohepatitis (NASH), where incidence rates are rapidly increasing due to modern life-styles, while treatment options are limited, expensive, and often ineffective.

ORIDIS Biomed uses its proprietary TISSOMICST[™] platform also in its own research and development programs. In addition, the Company commercializes the TISSOMICST[™] research platform in collaborations with industrial partners.

ORIDIS Biomed is a privately held company, based in Graz, Austria

About TISSOMICST[™]

TISSOMICST[™] is a proprietary disease-driven research platform enabling the medical validation of drug discovery approaches and biomarkers. ORIDIS Biomed has a license from the Medical University of Graz, Austria for the commercial access to BioResource-Med biobank, one of the world's largest collections of diseased human tissues and associated medical data. TISSOMICST[™] has been successfully applied in co-operations and partnerships with leading pharmaceutical and biotechnology companies to deliver medical validation to their drug discovery or biomarker programs using optimized genomic and proteomic approaches.

Dr. Peter Hecht joined ORIDIS Biomed in 2005, taking over the position of Chief Executive Officer from founder Prof. Kurt Zatloukal. Dr. Hecht brings more than 20 years of operational and commercial research management experience to ORIDIS Biomed. Prior to joining ORIDIS Biomed, he was Managing Director of Tripos UK, the discovery research business unit of the drug discovery and chemistry research company Tripos. Previously, he worked in pharmaceutical research at the Novartis Institute for Biomedical Research in Vienna, Austria.

QIAGEN GmbH

Address	QIAGEN Strasse 1; 40724 - Hilden (Germany)
Phone / Fax	T:00492103290
Size	250+
Organisation type	Company

Contact Person

Name	Gerhard Hofer
Position	Regionalleiter Sales Deutschland Süd/Öst
Phone / Fax	T:00492103290
Email	Gerhard.Hofer@qiagen.com

Further Details

Short title	QIAcube			
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Both Requested Offered	Networking: Services: Lecture/Poster:	Both PO3
Areas of activity:	Biotechnology Diagnostics Molecular Biology Cell Biology Instruments and equipment			

QIAGEN Vertriebs GmbH

Address	Löwengasse 47/6; 1030 - Wien (Austria)
Phone / Fax	T:0043 664 1860554
www	www.qiagen.com
Size	250+
Organisation type	Company

Contact Person

Name	Mag. Brigitte Tschuden
Position	Wiss. Aussendienst Österreich
Phone / Fax	T:0043 664 1860554
Email	brigitte.tschuden@qiagen.com
www	www.qiagen.com

Further Details

Short title	Sample and Assay Technologies			
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Both Requested Offered	Networking: Services: Lecture/Poster:	Both Offered
Areas of activity:	Biotechnology (Bio-)Medical Technology Diagnostics Molecular Biology Cell Biology Instruments and equipment Services			

Project description

Present QIAGEN as industry partner, interested in licensing new procedures and technologies. Present QIAGEN as supplier of Sample and Assay Technologies for research and diagnostics. Present solutions for biobanking (eg. sample stabilisation and preparation). Support networking with relevant QIAGEN departments (eg. business development, R&D)

Type of co-operation and qualification of co-operation partner

Find labs willing to have early access to innovative products and provide us with evaluation data. Discuss optimisation of workflows and understand the partners needs.

Short description of company/working group

QIAGEN is the worldwide leading provider of sample and assay technologies for research in life sciences, applied testing and molecular diagnostics. QIAGEN's products are considered standards in areas such as pre-analytical sample preparation and assay solutions. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions for sample collection, nucleic acid and protein handling, separation, and purification and open and target specific assays. The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN's headquarters are based in Hilden, Germany. QIAGEN employs more than 1,900 people worldwide.

REMP AG

Address	Weststrasse 12; 3672 - Oberdiessbach (Switzerland)
Phone / Fax	T:+41 31 770 7070 / F:+41 31 770 7266
www	www.remp.com
Size	51-250
Organisation type	Company

Contact Person

Name	Dipl. Ing. Donat Elsener
Position	Vice President of Innovation
Phone / Fax	T:+41 31 770 7070 / F:+41 31 770 7266
Email	donat.elsener@remp.com
www	www.remp.com

Further Details

Short title	Establishing Biobanking facilities and SOPs		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Both	
	Licensing:	Services:	
	Manufacturing:	Lecture/Poster:	L05 P10
	Sales and Marketing:		
Areas of activity:	Instruments and equipment		

Project description

Providing high quality and well characterized biological samples has become a key element for basic and applied medical and pharmaceutical research. The growing demand has not only on a quantitative but also on a qualitative level fueled the need for automated storage and retrieval systems operating at temperature as low as -80°C to ensure stable storage conditions and sample integrity even during retrieval cycles.

The negative impact of temperature fluctuations during long term storage of biological samples has been a topic of less interest in research. REMP would encourage to set up a project to study the influence of temperature fluctuations during long term storage of plasma on gene expression profiles.

In addition REMP would be happy to discuss needs and solutions in the area of sample management, especially but not restricted to Biobanking.

Type of co-operation and qualification of co-operation partner

The academic partner would need to have access to high quality samples and analytical methods. The mid to long term horizon of such a project would require an appropriate environment to ensure stable research methods over time.

Short description of company/working group

REMP is a global leader in the supply of automated storage and retrieval systems for sample management in the pharmaceutical and biotechnology industries. Sample management is the key foundation to the drug discovery and development process, compound and bio-specimen libraries represent one of the most important assets of Life Science companies and are becoming a precious element for basic research. The REMP product line includes systems, workstations, consumables, software applications for sample storage and retrieval, cherry-picking, climate control, plate replication and reformatting, powder dosing, vial weighing, tube capping and uncapping, thermal sealing, and piercing. REMP is proud to have built the worlds first operational large scale fully automated -80°C biorepository. Founded in 1986, REMP has over 140 employees worldwide and is a Tecan Group company (www.tecan.com).

Research Centre Applied Biocatalysis GmbH

Address	Petersgasse 14/5; 8010 - Graz (Austria)
Phone / Fax	T:316 873 4074
www	www.a-b.at
Size	51-250
Organisation type	Research Organisation

Contact Person

Name	Univ.-Prof. Dr. Anton Glieder
Position	key researcher
Phone / Fax	T:316 873 4074
Email	a.glieder@tugraz.at
www	www.a-b.at

Further Details

Short title	Colaborative research between industry and academia in industrial biotechnology			
Type of co-operation (Offered, Requested)	Research Project:	Both	Networking:	Both
	Licensing:	Offered	Services:	Both
	Manufacturing:		Lecture/Poster:	L16
	Sales and Marketing:			
Areas of activity:	Biotechnology (Bio-)Medical Technology Pharmaceutical Research Molecular Biology Cell Biology Biochemistry Nanotechnology Services			

Project description

Based on long-year experience the Research Centre Applied Biocatalysis in Graz offers its expertise for a cooperation to solve problems and develop processes for industrial biotechnology.

The special strength of the Research Centre Applied Biocatalysis lies in the availability of know-how in all areas to be covered when working in this highly interdisciplinary field in one location: Biotechnology, Bioprocess Engineering, Genetics, Spectroscopy, Analytics, Microbiology, Structural Biology, Bioinformatics and Organic Chemistry.

Examples for our expertise are:

- Synthesis of enantiomerically pure compounds by enzyme-catalysed reactions.
- Synthesis of human metabolites of active pharmaceutical ingredients
- Whole cell biotransformations
- Enrichment techniques, screening for microorganisms
- Strain library
- Cloning and overexpression

- Design development and production of tailor-made enzymes by directed evolution and site-directed mutagenesis
- Structural biology
- Bioinformatics and biosensors
- Development of protein production techniques, structural biology
- Enzymatic modification and functionalisation of synthetic materials (e.g. bioactive polymers)

Currently together with partners from Viena and Tirol, we plan to extend the currently running collaborations to a focused and strong activity in industrial biotechnology and to apply for a K2 centre for industrial biotechnology.

Type of co-operation and qualification of co-operation partner

We are open to extend our current scientific partnerships with further interested excellent industrial and academic partners for highly interdisciplinary collaborative research in the area of industrial biotechnology, which follows the demands as described by the guidelines of the K-centre funding program Comet, i.e. especially:

-) highly innovative research
-) carried out by top researchers of the respective field of science
-) pre-competitive research partly financed by industrial partners
-) technology leadership

Short description of company/working group

The Research Centre Applied Biocatalysis is devoted to joint research of academic and industrial partners within all areas of industrial biotechnology. Caused by the highly interdisciplinary character of biocatalysis both fundamental investigations and product-oriented research is performed.

Based on long-year experience the Research Centre Applied Biocatalysis in Graz offers its expertise for a cooperation to solve problems and develop processes for industrial biocatalysis. The staff of the Centre consists of about 60 persons directly employed. In addition about 40 researchers and employees at the two Graz universities and the University of Natural Resources and Applied Life Sciences Vienna are engaged on a part time basis. The special strength of the Research Centre Applied Biocatalysis lies in the availability of know-how in all areas to be covered when working in this highly interdisciplinary field in one location: Biotechnology, Bioprocess Engineering, Genetics, Spectroscopy, Analytics, Microbiology, Structural Biology, Bioinformatics and Organic Chemistry.

Roche Diagnostics Graz GmbH

Address	Kratkystr.2; 8020 - Graz (Austria)
Phone / Fax	T:+43 316 27787-3458
Size	250+
Organisation type	Company

Contact Person

Name	Martin Hajnsek
Position	Senior Scientist
Phone / Fax	T:+43 316 27787-3458
Email	martin.hajnsek@roche.com

Further Details

Short title	sensor platform for continuous glucose monitoring		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Both L12 P24
Areas of activity:	Diagnostics Instruments and equipment		

Project description

Monitoring of the glucose concentration in the subcutaneous abdominal region is of essential interest with respect to the treatment of diabetic patients.

To ensure accurate and continuous data readings of the patient's glucose levels, a sensor platform for various applications was developed based on manganese dioxide technology. This platform uses Glucose Oxidase to produce hydrogen peroxide equimolar to glucose and a screen-printed manganese dioxide layer as electrical transducer.

The sensor platform is currently developed in close cooperation with Roche Diabetes Care in Mannheim for use in a microdialysis device and in a transcutaneously implanted needle type sensor.

The unique feature of this system is the porous manganese dioxide structure which enables a nearly 100% oxygen recycling process because the enzyme is immobilised inside this porous structure in immediate vicinity to the transducer.

This structure results in:

- A very low oxygen dependency
- Very high hydrogen peroxide efficiency
- High current density and high signal/noise ratio
- nearly 100% depletion of hydrogen peroxide and therefore negligible cytotoxic effects

This poster presents the sensor chemistry, in vivo data of a clinical study of the in-vivo sensor and ex-vivo data of a clinical study of the microdialysis system.

Type of co-operation and qualification of co-operation partner

we are not looking for a specific cooperation

Short description of company/working group

Roche Diagnostics Graz GmbH (formerly AVL medical instruments) is a member of the Roche Diagnostics division, the world leading company in diagnostics, and is a global player in the bloodgas - and point of care market.

Roche Diagnostics Graz GmbH

Address	Kratkystrasse 2; 8020 - Graz (Austria)
Phone / Fax	T:+4331627787-4680 / F:+4331627787-6350
Size	250+
Organisation type	Company

Contact Person

Name	Dr Horst Ruether
Position	Head of Instrument Platform
Phone / Fax	T:+4331627787-4680 / F:+4331627787-6350
Email	horst.ruether@roche.com

Further Details

Areas of activity: Diagnostics

Science Park Graz

Address	Plüddemanngasse 39/2; 8010 - Graz (Austria)
Phone / Fax	T:0316/873-9102 / F:0316 - 873 9109
www	www.sciencepark.at
Size	1-10
Organisation type	Company

Contact Person

Name	Mag. Bernhard Weber
Position	Business Development
Phone / Fax	T:0316/873-9102 / F:0316 - 873 9109
Email	weber@sciencepark.at
www	www.sciencepark.at

Further Details

Short title	Business incubator for academic spin-offs		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Both Both P18
Areas of activity:	Services		

Project description

Sector: technology transfer, business development, consulting, funding academic spin-offs, business incubator
The non-profit organization Science Park Graz is the university incubator in Graz run by the three universities (TU Graz, MUG, KFU) and the Steirischen Wirtschaftsförderung. Scientists with an innovative business idea are supported with individual coaching during the development of a business plan and with entrepreneurship training courses. SPG offers excellent starting conditions for scientists who want to realize their business ideas on the market: coaching, training, offices, R&D infrastructure, funding/grants.

Type of co-operation and qualification of co-operation partner

Type of co-operation sought:
Type of partner sought:

Short description of company/working group

Support for scientists interested in transferring their ideas to the market place and starting an own company:
<ul style="list-style-type: none"> - Evaluation of business model - Business Development - Entrepreneurship training - Access to research facilities and university laboratories - Subject-specific tutoring and coaching by SPG, academic mentors and business mentors - Grants for research and development, and external consultants - Interest free loans - SPG-network (academia, industry) - Cooperation with public funding agencies, private investors, venture capital firms - International relationships

Science Park Graz

Address	Plüddemangasse 39; 8010 - Graz (Austria)
Phone / Fax	T:0664 - 4107430
Size	1-10
Organisation type	Other

Contact Person

Name	Dr. Kirsten Tangemann
Position	CEO
Phone / Fax	T:0664 - 4107430
Email	kirsten.tangemann@gmail.com

Further Details

Short title	Scientist with international R&D experience in academia and pharmaceutical companies and business know-how as CEO of an academic business incubator		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	
Areas of activity:	Biotechnology (Bio-)Medical Technology Diagnostics Pharmaceutical Research Biochemistry Imaging Services		

SFG Steirische Wirtschaftsförderung

Address	Nikolaiplatz 2; 8020 - Graz (Austria)
Phone / Fax	T:+43/316/7093-330
www	http://sfg.at
Size	51-250
Organisation type	Other

Contact Person

Name	Mag. Gerald Fasching
Position	Key Account Manager
Phone / Fax	T:+43/316/7093-330
Email	gerald.fasching@sfg.at
www	http://sfg.at

Further Details

Short title	sfg offers for production and service companies a wide range of support possibilities		
Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:	Offered
Areas of activity:	Services		

Project description

our support programmes for companies: Consulting Services Innovative Investments Market Development Guarantee
--

Research and Development
 Silent Partnerships
 Skills Development of Qualified Employees
 Start-Up Entrepreneurs
 TRIALITY 2006
 Venture Capital

Type of co-operation and qualification of co-operation partner

We expect a new business establishment, investment in a new facility or the expansion of an existing facility or a research project in styria.

Short description of company/working group

sfg is the business support and development institution of the region of styria with the main target to help Styrian enterprises to accelerate their economic development and success.
 services reach from consulting to several support programs - guarantees, VC, silent partnerships, loans, sfg is also the first point of contact for foreign investors, we raise, support and steer cluster and network organisations, technology parks centers of competence.

Siemens Corporate Technology

Address	Otto-Hahn-Ring 6; 81739 - Muenchen (Germany)
Phone / Fax	T:+49 (89) 636-55734 / F:+49 (89) 636-49767
www	www.siemens.com
Size	250+
Organisation type	Company

Contact Person

Name	Priv. Doz. Dr. habil. Martin Stetter
Position	research director
Phone / Fax	T:+49 (89) 636-55734 / F:+49 (89) 636-49767
Email	stetter@siemens.com
www	www.siemens.com

Further Details

Short title	IT Solutions and Databases - Learning Systems		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Services:	
	Manufacturing: Sales and Marketing:	Lecture/Poster:	L01
Areas of activity:	Information processing & storage, (Bio-)Medical Technology Instruments and equipment, Imaging Services		

Siemens AG Österreich - Medical Solutions

Address	Straßganger Straße 315; 8054 - Graz (Austria)
Phone / Fax	T:+43 5 17 07-6 33 57
www	http://www.medical.siemens.com
Size	250+
Organisation type	Company

Contact Person

Name	Ing. Karl Rößl
Position	regional manager south
Phone / Fax	T:+43 5 17 07-6 33 57
Email	karl.roessl@siemens.com
www	http://www.medical.siemens.com

Contact Person

Name	Ing. Wolfgang Gruber
Position	Business Manager Molecular Imaging
Phone / Fax	T:+43-676-3000-193
Email	wolfgang.c.gruber@siemens.com

Contact Person

Name	DI Dr. Gerhard Geisswinkler
Position	General Manager
Phone / Fax	T:+43 5 17 07-6 3204
Email	gerhard.geisswinkler@siemens.com
www	http://www.medical.siemens.com

Contact Person

Name	Ing. Gerhard Zötsch
Position	Sales Manager
Phone / Fax	T:+43 5 17 07
Email	gehard.zoetsch@siemens.com
www	http://www.medical.siemens.com

Contact Person

Name	Mag. Daniela Rosenauer
Position	sales manager
Phone / Fax	T:+43 5 17 07
Email	daniela.rosenauer@siemens.com
www	http://www.medical.siemens.com

Further Details

Short title	Molecular Imaging and Molecular Medicine - Clinical and Preclinical Aspects		
Type of co-operation (Offered, Requested)	Research Project:	Requested	Networking:
	Licensing:		Services:
	Manufacturing:		Lecture/Poster:
	Sales and Marketing:		
Areas of activity:	Information processing & storage (Bio-)Medical Technology Diagnostics Instruments and equipment Imaging		

Project description

Molecular Imaging

- is non invasive
- provides information on cellular and/or molecular level
- detects and localizes individual molecular markers related to a disease (e.g. receptors of cell surface, enzymes, molecules of signal cascade) and therapeutic pharmaceuticals (e.g. Liposome, viral particles) with the help of specific tracers (and contrast agents)
- MRT, ultrasound, and near IR fluorescence imaging are gaining momentum
- SPECT and PET together with its multi-modality applications (PET/CT, SPECT/CT, MR-PET) provide the foundation of Molecular Imaging. Development of advanced tracers is key.

Type of co-operation and qualification of co-operation partner

Cooperation in Research Project

Short description of company/working group

Siemens, headquartered in Berlin and Munich, is one of the worlds largest electrical engineering and electronics companies. Siemens provides innovative technologies and comprehensive know-how to benefit customers in 190 countries. Founded more than 150 years ago, the company is active in the areas of Information and Communications, Automation and Control, Power, Transportation, Medical, and Lighting.

Technology Exploitation Office, Graz University of Technology

Address	Steyrergasse 17; 8010 - Graz (Austria)
Phone / Fax	T:+43 (0)316 873 5434
Size	250+
Organisation type	University

Contact Person

Name	DI Dr. Alexandra Loidl
Position	Project Manager Life Science
Phone / Fax	T:+43 (0)316 873 5434
Email	loidl@tugraz.at

Further Details

Short title				
Type of co-operation (Offered, Requested)	Research Project:	Offered	Networking:	Both
	Licensing:	Requested	Services:	Both
	Manufacturing:	Requested	Lecture/Poster:	
	Sales and Marketing:	Requested		
Areas of activity:	Biotechnology, (Bio-)Medical Technology			
	Pharmaceutical Research			
	Molecular Biology			
	Biochemistry			
	Nanotechnology			

TU Graz Institute RNS

Address	Inffeldg. 21A; 0 - Graz (Austria)
Phone / Fax	T:(316) 873 7978
Size	250+
Organisation type	University

Contact Person

Name	Johannes Khinast
Position	Univ. Prof.
Phone / Fax	T:(316) 873 7978
Email	khinast@tugraz.at

Further Details

Short title	Development of a Pharmaceutical Engineering Center in Styria		
Type of co-operation (Offered, Requested)	Research Project: Both	Networking: Both	Services: Requested
	Manufacturing: L14	Lecture/Poster: L14	
Areas of activity:	Pharmaceutical Research Instruments and equipment Nanotechnology		

Project description

During the last years significant efforts have been devoted to building up a Center for Pharmaceutical Engineering in Styria. The first step was to institutionalize a Chair for Pharmaceutical and Process Engineering at the TU Graz. In a second step, a consortium of 16 Institutes from the TU GRaz, University of Graz, JOANNEUM RESEARCH and Austrian Academy of Sciences as well as 15 pharmaceutical and diagnostic companies have applied for a K1 competence center. The purpose of the meetings and the oral presentation is to inform companies about these initiatives and to offer potential cooperations.

Type of co-operation and qualification of co-operation partner

Interest in pharmaceutical and diagnostics manufacturing and in shared research projects or cooperations between academia and industry. Cooperations partners should be companies or academic institutes.

Short description of company/working group

Our institutes focus is the production of pharmaceuticals and diagnostics with a focus on reactor technology, pharmaceutical particle technology, manufacturing operations, process simulation, process analytical technology, quality by design, etc.

University of Debrecen

Address	Nagyedrdei krt. 98.; 4032 - Debrecen (Hungary)
Phone / Fax	T:+365242789
www	http://www.sensocrinepharma.com
Size	1-10
Organisation type	University

Contact Person

Name	Barna Peitl
Position	Assistant Professor
Phone / Fax	T:+3652427899
Email	info@sensocrinepharma.com
www	http://www.sensocrinepharma.com

Further Details

Short title	The aim of Sensocrine Pharma Ltd, a Specialty Pharma Co is to renew generic drugs for the treatment of diabetes (type 2 diabetes & obesity).		
Type of	Research Project: Offered	Networking: Requested	

co-operation (Offered, Requested)	Licensing: Manufacturing: Sales and Marketing:	Offered	Services: Lecture/Poster:	P17
Areas of activity:	Pharmaceutical Research Drug Targeting			

Project description

The business mission of Sensocrine Pharma Ltd. is the world-wide commercialization of its core science & technology, i.e., sensocrine pharmacotherapy, a leading discovery of the founders, addressing the release of systemic hormone-like substances by sensory nerves. The corporate objective is the development of novel drugs up to the clinical proof of concept (phase II/a study), when the drug candidates will be licensed out to large pharmaceutical companies. Success factors are the proprietary rights provided by proprietary patent applications (new combinations, second medical use), short time-to-market development, and the low operation costs at a start-up company. Customer benefits include the improved efficacy and safety of the treatments by new, cost-effective drugs. Investor benefits may arise from the rapidly growing Specialty Pharma business segment, in general, and the remarkable added value provided by the company's sensocrine core science and technology, in particular.

Type of co-operation and qualification of co-operation partner

Type of co-operation sought:
- License Agreement
- Commercial Agreement with Technical Assistance
Type of partner sought:
Industry
Specific area of activity of the partner:
Distributor or producer of medical

Short description of company/working group

SENSOCRINE Pharma Ltd. is a technology-based start-up company devoted to develop small molecules of high therapeutic value for the prevention and treatment of poorly served human diseases of high incidence. Established in Debrecen, Hungary in 2006, the company started its operation with a specialty pharma project, in order to develop its first lead product for the treatment of diabetes (diabetes associated with obesity).

University of Graz - Research Services

Address	Universitätsplatz 4; 8010 - Graz (Austria)
Phone / Fax	T:+43 (0) 316 380-3994 / F:+43 (0) 316 380-9034
www	www.uni-graz.at/forschung
Size	250+
Organisation type	University

Contact Person

Name	Dipl.-Ing. (FH) Michael Freidl
Position	Intellectual Property Rights
Phone / Fax	T:+43 (0) 316 380-3994 / F:+43 (0) 316 380-9034
Email	michael.freidl@uni-graz.at
www	www.uni-graz.at/forschung

Further Details

Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:
Areas of activity:	Services	

University of Graz, Office of Research Services

Address	Universitaetsplatz 3; 8010 - Graz (Austria)
Phone / Fax	T:+43 (0) 316 380-1287 / F:+43 (0) 316 380-9034
www	www.uni-graz.at/forschung
Size	250+
Organisation type	University

Contact Person

Name	Dr. Manfred Hall
Position	Knowledge Transfer
Phone / Fax	T:+43 (0) 316 380-1287 / F:+43 (0) 316 380-9034
Email	forschung@uni-graz.at
www	www.uni-graz.at/forschung

Further Details

Type of co-operation (Offered, Requested)	Research Project: Licensing: Manufacturing: Sales and Marketing:	Networking: Services: Lecture/Poster:
Areas of activity:	Services	

University of Maribor

Address	Vrbanska ulica 30; 2000 - Maribor (Slovenia)
Phone / Fax	T:++38641476578
Size	250+
Organisation type	University

Contact Person

Name	Aleš Goropevšek
Position	Research Assistant
Phone / Fax	T:++38641476578
Email	goropevsek@yahoo.com

Further Details

Short title	Monitoring intracellular signalling pathways in subsets of immune cells at the single cell level		
Type of co-operation (Offered, Requested)	Research Project: Requested	Networking: Services: Lecture/Poster:	Offered PO6
Areas of activity:	Clinical Studies (Bio-)Medical Technology Diagnostics Cell Biology Biochemistry		

Project description

Identification of cytokines TNF and IFN- γ , as major factors in the pathogenesis of diseases such as rheumatoid arthritis and systemic lupus erythematosus (SLE) represent a substantial improvement in understanding of (autoimmune) diseases. However, little is known about intracellular signalling pathways that are activated in response to those clinically relevant cytokines, and even less is known about their changes in (autoimmune) disease states. Most of signaling pathways that lead from surface receptors to gene regulation, mediate signals through phosphorylation and dephosphorylation of proteins. Among many signalling pathways, important for immune activation, Jak-Stat pathways are essential in cytokine activity. A series of assay systems for flow cytometric-based biochemical analysis at the single-cell level for kinase and phosphoprotein profiling have been developed in our lab. These systems have possibility of simultaneous measurement of several proteins, kinases and their phospho-epitopes per cell. This gives opportunity to study signal pathways also in for example autoimmune and chronic inflammatory diseases, as the analysing systems are adapted to immunocytes for example in peripheral blood.

Innovative Aspects:

until recently it was not possible to monitor signalling pathways on the level of single cell and studies which define activation profiles of subpopulations of immune cells in response to interferons and other cytokines are very limited. Measurement of such signalling events has been limited to cell lines or bulk cell-lysis assays. These analyses do not give clear view on phosphorylation of proteins at the single cell level, especially not in subpopulations of lymphocytes and dendritic cells that are essential in immune response. Therefore true understanding and monitoring of cell signalling dysfunctions during disease processes in patient samples has been beyond reach. It is now possible, by flow cytometry and detection of intracellular phospho-epitopes, to monitor signalling pathways on the single cell level. Moreover, signalling events can be measured after direct stimulation of whole blood.

Main Advantages:

our methods enable direct analysis of samples and do not demand isolation of mononuclear cells not even sorting of cell fractions, because manipulation of cells can result in changes of intracellular signalling cascades. Isolation also removes cells from their natural environment, which includes for example serum proteins - cytokines in whole blood.

Type of co-operation and qualification of co-operation partner

We are seeking partners for the co-development of our analytical methods and want to offer our research services to all organizations involved in biomedical research.

Short description of company/working group

University laboratory for Microbiology, Biochemistry, Molecular Biology and Biotechnology

University of Maribor

Address	Vrabanska Ulica 30; 2000 - Maribor (Slovenia)
Phone / Fax	T:+38631221387
Size	250+
Organisation type	University

Contact Person

Name	Walter Chingwaru
Position	researcher
Phone / Fax	T:+38631221387
Email	wchingwaru@yahoo.co.uk

Further Details

Short title	Health benefits of Tylosema (marama beans) and value added products to niche markets (Southern Africa)		
Type of co-operation	Research Project:	Requested	Networking:
(Offered, Requested)	Licensing:		Services:
	Manufacturing:	Requested	Lecture/Poster: P11
	Sales and Marketing:		

Areas of activity: (Bio-)Medical Technology
Cell Biology
Biochemistry

Project description

1. We are investigating antimicrobial activity of Tylosema species, and immunological response of cells to presence of Tylosema beans.
2. We are also investigating the antimicrobial effects (antiviral, antibacterial) of probiotic bacteria
3. We isolate animal cell-lines for in vitro testing of various compounds, especially plant extracts, and microorganisms

Type of co-operation and qualification of co-operation partner

A research institute with resources that complement what our laboratory

Short description of company/working group

University laboratory for Microbiology, Biochemistry, Molecular Biology and Biotechnology

Organisers



...in cooperation with the following partner organisations



...financially supported by



ORGANISATION AND INFORMATION

Dr. Heidi Schmitt

Technology Transfer — Industry Cooperation
Research Management Office

Medical University of Graz, Auenbruggerplatz 2, A-8036 Graz
phone: +43-316-385-72018, Fax: +43-316-385-72030, E-Mail: heidi.schmitt@meduni-graz.at

www.meduni-graz.at/partneringday